Vorinostat (SAHA, MK0683)

Catalog No.S1047 Synonyms: SAHA, MK0683, suberoylanilide hydroxamic acid

Molecular Weight(MW): 264.3

Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay.

Cited by 259 Publications

Cell, 2019, 176(1-2):198-212

PubMed: 30503211 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2018, 174(3):536-548.e21

PubMed: 29961578 ( click the link to review the publication )

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Cancer Discov, 2017, 7(12):1450-1463

PubMed: 28963352 ( click the link to review the publication )

Cancer Cell, 2016, 29(3):311-323

PubMed: 26977882 ( click the link to review the publication )

Nat Biotechnol, 2015, 10.1038/nbt.3130

PubMed: 25751058 ( click the link to review the publication )

Nat Med, 2015, 21(10):1163-71

PubMed: 26390243 ( click the link to review the publication )

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

Cell, 2014, 158(5):989-99

PubMed: 25131989 ( click the link to review the publication )

Nature, 2011, 471(7337):235-9

PubMed: 21390130 ( click the link to review the publication )

Nat Biotechnol, 2011, 29(3):255-65

PubMed: 21258344 ( click the link to review the publication )

Nat Commun, 2019, 10(1):4192

PubMed: 31519896 ( click the link to review the publication )

J Pineal Res, 2019, 66(3):e12556

PubMed: 30648757 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2018.211110

PubMed: 30846494 ( click the link to review the publication )

Haematologica, 2019, 104(11):2225-2240

PubMed: 30819918 ( click the link to review the publication )

Theranostics, 2019, 9(2):540-553

PubMed: 30809292 ( click the link to review the publication )

Cancer Res, 2019, 79(7):1658-1670

PubMed: 30737231 ( click the link to review the publication )

Cell Rep, 2019, 27(11):3331-3344

PubMed: 31189115 ( click the link to review the publication )

Elife, 2019, 8

PubMed: 30652970 ( click the link to review the publication )

Mol Ther, 2019, 27(5):1039-1050

PubMed: 30852137 ( click the link to review the publication )

Mol Ther, 2019, 27(5):1039-1050

PubMed: 30852137 ( click the link to review the publication )

Cancers (Basel), 2019, 11(4)

PubMed: 30935067 ( click the link to review the publication )
Clin Epigenetics, 2019, 11(1):85

PubMed: 31142371 ( click the link to review the publication )

Acta Pharm Sin B, 2019, 9(5):937-951

PubMed: 31649844 ( click the link to review the publication )

Cells, 2019, 8(12)

PubMed: 31795298 ( click the link to review the publication )

Cancer Discov, 2019, 9(4):526-545

PubMed: 30709805 ( click the link to review the publication )

Front Immunol, 2019, 9:3162

PubMed: 30723480 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(5):900-908

PubMed: 30824609 ( click the link to review the publication )

Mol Oncol, 2019, 10.1002/1878-0261.12607

PubMed: 31782885 ( click the link to review the publication )

Epigenetics, 2019, 10.1080/15592294.2019.1656155

PubMed: 31423895 ( click the link to review the publication )

Epigenetics, 2019, 14(8):791-803

PubMed: 31088315 ( click the link to review the publication )

Epigenetics, 2019, 10.1080/15592294.2019.1656156

PubMed: 31423932 ( click the link to review the publication )

AIDS, 2019, 33(2):199-209

PubMed: 30562171 ( click the link to review the publication )

Hum Mol Genet, 2019, 10.1093/hmg/ddz254

PubMed: 31691806 ( click the link to review the publication )

Pharmacol Res, 2019, 139:524-534

PubMed: 30366100 ( click the link to review the publication )

Pharmacol Res, 2019, 146:104281

PubMed: 31125601 ( click the link to review the publication )

Mol Pharm, 2019, 16(9):3904-3915

PubMed: 31318566 ( click the link to review the publication )

Bone, 2019, 125:112-121

PubMed: 31100533 ( click the link to review the publication )

Front Cell Neurosci, 2019, 13:468

PubMed: 31708743 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(13)

PubMed: 31269745 ( click the link to review the publication )

Apoptosis, 2019, 24(5-6):404-413

PubMed: 30997620 ( click the link to review the publication )

J Biol Chem, 2019, 294(12):4437-4449

PubMed: 30670592 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 40(5):677-688

PubMed: 30224636 ( click the link to review the publication )

NMR Biomed, 2019, 32(2):e4044

PubMed: 30561869 ( click the link to review the publication )

Stem Cells Dev, 2019, 28(7):438-453

PubMed: 30667343 ( click the link to review the publication )

Chem Biol Interact, 2019, 306:54-61

PubMed: 30958996 ( click the link to review the publication )
Gene Ther, 2019, 26(3-4):75-85

PubMed: 30538307 ( click the link to review the publication )

Cancer Med, 2019, 8(14):6383-6392

PubMed: 31456359 ( click the link to review the publication )

Tuberculosis (Edinb), 2019, 118:101861

PubMed: 31526947 ( click the link to review the publication )

PLoS One, 2019, 14(6):e0218382

PubMed: 31206526 ( click the link to review the publication )

Exp Hematol, 2019, 72:60-71

PubMed: 30769020 ( click the link to review the publication )

Nucl Med Biol, 2019, 74-75:1-11

PubMed: 31421440 ( click the link to review the publication )

Alcohol, 2019, 78:79-87

PubMed: 30851364 ( click the link to review the publication )

Anticancer Res, 2019, 39(7):3579-3584

PubMed: 31262882 ( click the link to review the publication )

Res Vet Sci, 2019, 126:207-212

PubMed: 31610471 ( click the link to review the publication )

Exp Ther Med, 2019, 17(6):4547-4553

PubMed: 31186678 ( click the link to review the publication )

Medicina (Kaunas), 2019, 55(2)

PubMed: 30700046 ( click the link to review the publication )

Cell Host Microbe, 2018, 24(5):689-702

PubMed: 30344003 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(16):3941-3954

PubMed: 29764852 ( click the link to review the publication )

Cancer Res, 2018, 78(10):2705-2720

PubMed: 29490948 ( click the link to review the publication )

J Control Release, 2018, 275:117-128

PubMed: 29474960 ( click the link to review the publication )

Haematologica, 2018, 103(4):679-687

PubMed: 29305415 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):32

PubMed: 29486795 ( click the link to review the publication )

Cancer Lett, 2018, 432:121-131

PubMed: 29890207 ( click the link to review the publication )

Sci Signal, 2018, 11(557)

PubMed: 30459282 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 37(1):153

PubMed: 30012171 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2767-2779

PubMed: 30232145 ( click the link to review the publication )

J Virol, 2018, 92(10)

PubMed: 29343578 ( click the link to review the publication )

Sci Rep, 2018, 8(1):3521

PubMed: 29476067 ( click the link to review the publication )

J Cell Biochem, 2018, 119(5):4193-4204

PubMed: 29274289 ( click the link to review the publication )
Exp Cell Res, 2018, 371(1):231-237

PubMed: 30107147 ( click the link to review the publication )

BMC Cancer, 2018, 18(1):466

PubMed: 29695239 ( click the link to review the publication )

Oncol Rep, 2018, 39(1):264-270

PubMed: 29115632 ( click the link to review the publication )

Ann Hematol, 2018, 97(5):839-849

PubMed: 29359239 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 498(3):481-486

PubMed: 29505792 ( click the link to review the publication )

AAPS PharmSciTech, 2018, 19(2):634-647

PubMed: 28948528 ( click the link to review the publication )

Cell Biochem Funct, 2018, 36(8):398-407

PubMed: 30484863 ( click the link to review the publication )

Nat Struct Mol Biol, 2017, 24(1):47-54

PubMed: 27870832 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(12):3139-3149

PubMed: 27986747 ( click the link to review the publication )

Haematologica, 2017, 102(4):736-745

PubMed: 27979926 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(12):3084-3096

PubMed: 27993968 ( click the link to review the publication )

Oncogene, 2017, 36(34):4859-4874

PubMed: 28414307 ( click the link to review the publication )

Br J Pharmacol, 2017, 174(20):3608-3622

PubMed: 28749535 ( click the link to review the publication )

Eur J Med Chem, 2017, 127:531-553

PubMed: 28109947 ( click the link to review the publication )

Cancer Sci, 2017, 108(7):1485-1492

PubMed: 28498513 ( click the link to review the publication )

Int J Mol Sci, 2017, 18(5)

PubMed: 28481295 ( click the link to review the publication )

J Biol Chem, 2017, 292(12):5043-5054

PubMed: 28167529 ( click the link to review the publication )

J Pharmacol Exp Ther, 2017, 363(2):211-220

PubMed: 28860353 ( click the link to review the publication )

Pharm Res, 2017, 34(3):668-679

PubMed: 28101809 ( click the link to review the publication )

Cancer Med, 2017, 6(11):2673-2685

PubMed: 29024573 ( click the link to review the publication )

Int J Cell Biol, 2017, 2017:6169310

PubMed: 28321257 ( click the link to review the publication )

Connect Tissue Res, 2017, 58(1):64-75

PubMed: 27404795 ( click the link to review the publication )

Pulm Pharmacol Ther, 2017, 44:88-95

PubMed: 28323055 ( click the link to review the publication )

Am J Surg, 2017, 213(4):645-651

PubMed: 28007318 ( click the link to review the publication )
Oncotarget, 2017, 9(1):512-523

PubMed: 29416632 ( click the link to review the publication )

Oncotarget, 2017, 8(31):51429-51446

PubMed: 28881658 ( click the link to review the publication )

Oncotarget, 2017, 8(31):51429-51446

PubMed: 28881658 ( click the link to review the publication )

CPT Pharmacometrics Syst Pharmacol, 2017, 6(11):756-764

PubMed: 29045072 ( click the link to review the publication )

Sci Rep, 2017, 7(1):2290

PubMed: 28536458 ( click the link to review the publication )

Oncotarget, 2017, 8(45):78480-78495

PubMed: 29108243 ( click the link to review the publication )

JCI Insight, 2017, 2(1):e85811

PubMed: 28097226 ( click the link to review the publication )

JCI Insight, 2017, 2(6):e90196

PubMed: 28352655 ( click the link to review the publication )

Oncotarget, 2017, 10.18632/oncotarget.15017

PubMed: 28157715 ( click the link to review the publication )

Oncotarget, 2017, 8(44):77254-77267

PubMed: 29100385 ( click the link to review the publication )

Ann Oncol, 2016, 27(3):508-13

PubMed: 26658891 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

Cancer Res, 2016, 76(23):7001-7011

PubMed: 27671680 ( click the link to review the publication )

Cancer Res, 2016, 76(8):2376-83

PubMed: 26941288 ( click the link to review the publication )

Int J Cancer, 2016, 139(1):194-204

PubMed: 26914605 ( click the link to review the publication )

Drug Discov Today, 2016, 21(9):1553-1560

PubMed: 27371506 ( click the link to review the publication )

J Med Chem, 2016, 59(4):1613-33

PubMed: 26681404 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(6):1364-75

PubMed: 27196750 ( click the link to review the publication )

Mol Cell Proteomics, 2016, 15(6):2076-92

PubMed: 27067055 ( click the link to review the publication )

Neuropharmacology, 2016, 107:111-121

PubMed: 26970016 ( click the link to review the publication )

Biochem Pharmacol, 2016, 102:130-140

PubMed: 26718586 ( click the link to review the publication )

Am J Pathol, 2016, 186(10):2701-8

PubMed: 27555113 ( click the link to review the publication )

J Biol Chem, 2016, 291(19):10131-47

PubMed: 27022024 ( click the link to review the publication )

Neurochem Int, 2016, 96:24-31

PubMed: 27103167 ( click the link to review the publication )
Int J Oncol, 2016, 49(6):2453-2463

PubMed: 27748897 ( click the link to review the publication )

Am J Physiol Heart Circ Physiol, 2016, 311(5):H1139-H1149

PubMed: 27638876 ( click the link to review the publication )

Cancer Biol Ther, 2016, 17(1):27-35

PubMed: 26575826 ( click the link to review the publication )

Anal Bioanal Chem, 2016, 408(13):3547-53

PubMed: 26968571 ( click the link to review the publication )

BMC Cancer, 2016, 16:667

PubMed: 27549189 ( click the link to review the publication )

J Hum Genet, 2016, 10.1038/jhg.2016.61

PubMed: 27251006 ( click the link to review the publication )

J Hum Genet, 2016, 10.1038/jhg.2016.61

PubMed: 27251006 ( click the link to review the publication )

Med Oncol, 2016, 33(2):11

PubMed: 26732474 ( click the link to review the publication )

Inflammation, 2016, 39(1):39-46

PubMed: 26228975 ( click the link to review the publication )

PLoS One, 2016, 11(1):e0145985

PubMed: 26726879 ( click the link to review the publication )

Onco Targets Ther, 2016, 9:6843-6855

PubMed: 27877053 ( click the link to review the publication )

Leuk Lymphoma, 2016, 57(3):692-9

PubMed: 26084206 ( click the link to review the publication )

Asian Pac J Trop Med, 2016, 9(6):572-6

PubMed: 27262069 ( click the link to review the publication )

Genet Mol Res, 2016, 15(4)

PubMed: 27819724 ( click the link to review the publication )

Oncotarget, 2016, 7(36):58142-58147

PubMed: 27494885 ( click the link to review the publication )

Sci Rep, 2016, 6:21678

PubMed: 26902929 ( click the link to review the publication )

Oncotarget, 2016, 7(6):6727-47

PubMed: 26734995 ( click the link to review the publication )

Nat Commun, 2015, 6:7888

PubMed: 26223951 ( click the link to review the publication )

EMBO Mol Med, 2015, 10.15252/emmm.201404396

PubMed: 25872941 ( click the link to review the publication )

EMBO Mol Med, 2015, 10.15252/emmm.201404580

PubMed: 25759362 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-14-2701

PubMed: 25813020 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(7):1628-38

PubMed: 25623213 ( click the link to review the publication )

Blood Cancer J, 2015, 5:e312

PubMed: 25978432 ( click the link to review the publication )

Int J Cancer, 2015, 136(11):2717-29

PubMed: ( click the link to review the publication )
Cancer Lett, 2015, 356(2 Pt B):828-36

PubMed: 25449774 ( click the link to review the publication )

Cancer Lett, 2015, 366(1):32-43

PubMed: 26028172 ( click the link to review the publication )

Breast Cancer Res, 2015, 17:33

PubMed: 25888415 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1657

PubMed: 25695609 ( click the link to review the publication )

Acta Neuropathol Commun, 2015, 3(1):22

PubMed: 25853389 ( click the link to review the publication )

Endocr Relat Cancer, 2015, 22(5):777-92

PubMed: 26206775 ( click the link to review the publication )

Br J Haematol, 2015, 168(3):371-83

PubMed: ( click the link to review the publication )

Epigenetics, 2015, 10.1080/15592294.2015.1039216

PubMed: 25923331 ( click the link to review the publication )

Am J Cancer Res, 2015, 5(4):1337-52

PubMed: 26101701 ( click the link to review the publication )

Neuropharmacology, 2015, 99:67-78

PubMed: 26188143 ( click the link to review the publication )

Biochemical Pharmacology, 2015, 94(2):79-90

PubMed: ( click the link to review the publication )

Biochem Pharmacol, 2015, 94(2):79-90

PubMed: 25600908 ( click the link to review the publication )

Biochemical Pharmacology, 2015, 94(2):79-90

PubMed: ( click the link to review the publication )

Apoptosis, 2015, 20(7):975-85

PubMed: 25835755 ( click the link to review the publication )

J Biol Chem, 2015, 290(8):5028-40

PubMed: 25540204 ( click the link to review the publication )

J Biol Chem, 2015, 290(39):23725-37

PubMed: 26269591 ( click the link to review the publication )

J Biol Chem, 2015, 290(3):1829-36

PubMed: 25492871 ( click the link to review the publication )

J Biol Chem, 2015, 290(8):5028-40

PubMed: ( click the link to review the publication )

BMC Cancer, 2015, 15(1):273

PubMed: 25880212 ( click the link to review the publication )

FEBS Lett, 2015, 589(10):1080-8

PubMed: 25816750 ( click the link to review the publication )

J Biotechnol, 2015, 10.1016/j.jbiotec.2015.02.029

PubMed: 25746901 ( click the link to review the publication )

Mol Med Rep, 2015, 12(3):4291-4297

PubMed: 26095064 ( click the link to review the publication )

Oncotarget, 2015, 6(18):15814-27

PubMed: 26158412 ( click the link to review the publication )

Sci Transl Med, 2014, 6(256):256ra135

PubMed: 25273096 ( click the link to review the publication )
Acta Neuropathol, 2014, 128(2):291-303

PubMed: 24839957 ( click the link to review the publication )

Nat Commun, 2014, 5:3361

PubMed: 24553445 ( click the link to review the publication )

Clin Cancer Res, 2014, 10.1158/1078-0432.CCR-14-0384

PubMed: 25355930 ( click the link to review the publication )

Int J Cancer, 2014, 135(7):1721-32

PubMed: 24615207 ( click the link to review the publication )

Diabetes, 2014, 63(9):2924-34

PubMed: 24722245 ( click the link to review the publication )

Oncogene, 2014, 33(25):3307-15

PubMed: 23995789 ( click the link to review the publication )

Cancer Lett, 2014, 10.1016/j.canlet.2014.10.034

PubMed: ( click the link to review the publication )

Cancer Lett, 2014, 351(1):50-8

PubMed: 24814395 ( click the link to review the publication )

PLoS Pathog, 2014, 10(4):e1004071

PubMed: 24722454 ( click the link to review the publication )

PLoS Pathog, 2014, 10(4):e1004071

PubMed: 24722454 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1134

PubMed: 24651437 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1177

PubMed: 24743732 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(12):2784-92

PubMed: 25319394 ( click the link to review the publication )

J Mol Biol, 2014, 426(20):3442-53

PubMed: 24657767 ( click the link to review the publication )

Hum Gene Ther, 2014, 25(7):599-608

PubMed: 24568341 ( click the link to review the publication )

J Biol Chem, 2014, 289(14):9918-25

PubMed: 24515107 ( click the link to review the publication )

Cancer Cell Int, 2014, 10.1186/s12935-014-0112-x

PubMed: ( click the link to review the publication )

Cancer Cell Int, 2014, 14(1):112

PubMed: 25546354 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(7):1280-9

PubMed: 24469401 ( click the link to review the publication )

Proteomics Clin Appl, 2014, 8(11-12):924-31

PubMed: 25091122 ( click the link to review the publication )

J Alzheimers Dis, 2014, 41(4):1193-205

PubMed: 24844691 ( click the link to review the publication )

Cancer Biol Ther, 2014, 15(5):578-85

PubMed: 24556916 ( click the link to review the publication )

BMC Cancer, 2014, 14(1):373

PubMed: 24886166 ( click the link to review the publication )

FEBS Lett, 2014, 588(9):1571-9

PubMed: 24607544 ( click the link to review the publication )
Mol Med Rep, 2014, 10(5):2729-35

PubMed: 25199623 ( click the link to review the publication )

Oncol Lett, 2014, 7(5):1673-1678

PubMed: 24765199 ( click the link to review the publication )

Pharmacol Res Perspect, 2014, 2(3):e00043

PubMed: 25505589 ( click the link to review the publication )

Head Neck, 2014, 10.1002/hed.23822.

PubMed: 24986420 ( click the link to review the publication )

Cytometry A, 2014, 85(1):78-87

PubMed: 24038859 ( click the link to review the publication )

Curr Pharm Desigh, 2014, 20(11):1874-80

PubMed: 23888956 ( click the link to review the publication )

Pharmacology Research Perspectives, 2014, 10.1002/prp2.43

PubMed: ( click the link to review the publication )

Oncotarget, 2014, 5(15):5965-77

PubMed: 25115389 ( click the link to review the publication )

Blood, 2013, 123(5):706-16

PubMed: 24319254 ( click the link to review the publication )

Nat Struct Mol Biol, 2013, 20(3):317-25

PubMed: 23377543 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2013, 111(3):E364-73

PubMed: 24395801 ( click the link to review the publication )

PLoS Biol, 2013, 12(1):e1001758

PubMed: 24409098 ( click the link to review the publication )

Cancer Res, 2013, 73(8):2428-34

PubMed: 23382048 ( click the link to review the publication )

Cell Rep, 2013, 5(6):1679-89

PubMed: 24360956 ( click the link to review the publication )

Int J Cancer, 2013, 132(9):2200-8

PubMed: 23024001 ( click the link to review the publication )

Neuropsychopharmacology, 2013, 38(9):1674-84

PubMed: 23474591 ( click the link to review the publication )

Oncogene, 2013, 33(33):4265-72

PubMed: 24292675 ( click the link to review the publication )

Oncogene, 2013, 32(10):1316-29

PubMed: 22543582 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e733

PubMed: 23868066 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e951

PubMed: 24309938 ( click the link to review the publication )

Br J Haematol, 2013, 160(2):188-98

PubMed: 23167276 ( click the link to review the publication )

AIDS, 2013, 27(18):2853-62

PubMed: 24189584 ( click the link to review the publication )

J Biol Chem, 2013, 288(35):25593-602

PubMed: 23878197 ( click the link to review the publication )

J Biol Chem, 2013, 288(20):14400-7

PubMed: 23539624 ( click the link to review the publication )
PLoS Comput Biol, 2013, 9(2):e1002887

PubMed: 23408876 ( click the link to review the publication )

Mol Carcinog, 2013, 52(3):218-28

PubMed: 22121107 ( click the link to review the publication )

Front Pharmacol, 2013, 4:44

PubMed: 23596417 ( click the link to review the publication )

Genes Brain Behav, 2013, 13(1):69-86

PubMed: 24286462 ( click the link to review the publication )

Cell Cycle, 2013, 12(13):2073-83

PubMed: 23759592 ( click the link to review the publication )

PLoS One, 2013, 8(1):e53766

PubMed: 23320102 ( click the link to review the publication )

J Thromb Thrombolysis, 2013, 35(2):185-92

PubMed: 23229086 ( click the link to review the publication )

J Exp Med, 2012, 209(1):35-50

PubMed: 22231305 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(14):3822-33

PubMed: 22623731 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(2):408-16

PubMed: 22038994 ( click the link to review the publication )

Cancer Res, 2012, 72(9):2251-61

PubMed: 22422937 ( click the link to review the publication )

Cell Death Differ, 2012, 19(12):2029-39

PubMed: 22858545 ( click the link to review the publication )

Cell Death Differ, 2012, 19(8):1317-27

PubMed: 22322857 ( click the link to review the publication )

Eur J Cancer, 2012, 48(7):1096-107

PubMed: 22154545 ( click the link to review the publication )

Diabetologia, 2012, 55(9):2421-31

PubMed: 22772764 ( click the link to review the publication )

FASEB J, 2012, 26(7):3032-41

PubMed: 22459148 ( click the link to review the publication )

J Neurochem, 2012, 123 Suppl 2:108-15

PubMed: 23050648 ( click the link to review the publication )

J Leukoc Biol, 2012, 91(5):701-9

PubMed: 22028329 ( click the link to review the publication )

J Biol Chem, 2012, 287(43):36609

PubMed: 22952229 ( click the link to review the publication )

Mol Carcinog, 2012, 52(6):459-74

PubMed: 22308110 ( click the link to review the publication )

Invest New Drugs, 2012, 30(2):541-7

PubMed: 21107885 ( click the link to review the publication )

Pharm Res, 2012, 29(7):1960-76

PubMed: 22415140 ( click the link to review the publication )

Oncol Rep, 2012, 28(1):105-10

PubMed: 22484732 ( click the link to review the publication )

PLoS One, 2012, 7(9):e44265

PubMed: 22957056 ( click the link to review the publication )
PLoS One, 2012, 7(12):e52335

PubMed: 23272238 ( click the link to review the publication )

PLoS One, 2012, 7(12):e52753

PubMed: 23300762 ( click the link to review the publication )

Chronobiol Int, 2012, 29(8):982-93

PubMed: 22891617 ( click the link to review the publication )

Biochem Biophys Res Co, 2012, 420(2):325-30

PubMed: 22425986 ( click the link to review the publication )

Pediatr Surg Int, 2012, 28(6):579-89

PubMed: 22526548 ( click the link to review the publication )

Protein Expr Purif, 2012, 86(1):45-52

PubMed: 21992606 ( click the link to review the publication )

Brain, 2011, 134(Pt 8):2408-21

PubMed: 21772061 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(9):2819-29

PubMed: 21357681 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(16):5311-21

PubMed: 21724551 ( click the link to review the publication )

Genes Dev, 2011, 25(24):2610-8

PubMed: 22016339 ( click the link to review the publication )

J Neurosci, 2011, 31(11):3990-9

PubMed: 21411642 ( click the link to review the publication )

J Transl Med, 2011, 9:37

PubMed: 21477288 ( click the link to review the publication )

Retrovirology, 2011, 2(3):411-23

PubMed: 21966324 ( click the link to review the publication )

Mol Med, 2011, 17(5-6):466-72

PubMed: 21424110 ( click the link to review the publication )

PLoS One, 2011, 6(7):e22739

PubMed: 21818379 ( click the link to review the publication )

BMC Neurosci, 2011, 12:50

PubMed: 21615950 ( click the link to review the publication )

Sci Signal, 2010, 3(146):ra80

PubMed: 21045206 ( click the link to review the publication )

J Pharmacol Exp Ther, 2010, 86(16):8765-72

PubMed: 20739454 ( click the link to review the publication )

Exp Dermatol, 2010, 19(12):1096-102

PubMed: 20629733 ( click the link to review the publication )

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description

Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay.

Targets

HDAC ^[1]
(Cell-free assay)

~10 nM

In vitro

Vorinostat inhibits the activities of HDAC1 and HDAC3 with IC50 of 10 nM and 20 nM, respectively. Vorinostat also results in a marked hyperacetylation of histone H4. ^[1] Vorinostat inhibits the growth of three prostate cancer cell lines LNCaP, PC-3 and TSU-Pr1 at micromolar concentrations (2.5-7.5 μM), and induces dose-dependent cell death in LNCaP cells. ^[2] Vorinostat treatment in MCF-7 cells inhibits cell proliferation at an IC50 of 0.75 μM resulting in the accumulation of cells in the G1 and G2-M phase of the cell cycle. Vorinostat also induces differentiation in the estrogen receptor-negative cell line SKBr-3 and the retinoblastoma-negative cell line MDA-468. ^[3] Vorinostat treatment at 1 μM for 8 hours or more is sufficient to irreversibly induce apoptosis of human multiple myeloma (MM) cells. The gene expression profiles of Vorinostat treated MM cells are not hallmarked by global transcriptional activation, but by coordinated transcriptional changes of specific functional groups of genes such as cytokine-induced proliferative/survival signaling cascades, oncogenes-tumor suppressor genes, regulators of apoptosis, DNA synthesis-repair and cell cycle, and proteasome-ubiquitin function. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
A20	MlrGT4lv[XOnIFHzd4F6		Mnm4NUBp	MonRSG1UVw>?	M4rXd4FvfGlvSFTBR\|Eh[WO2aY\peJkhf2m2aDDJR\|UxKG:oIECuNVEzKM7:TR?=	MYmxNVk3ODR6OR?=
Friend leukemic cell	NGi0NIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYO0b\|RPPTBizszN	M1G2[lczKGh?	MljYSG1UVw>?	MlTNTWM2OD1yLkm5JO69VQ>?	M{T6SFEzOTB7OUGz
K562	NHjTV2NMcW6jc3WgRZN{[Xl?		M1yyVlYhcA>?	NYq4cGo3TE2VTx?=	NUHC[HRCUW6qaXLpeIlwdiCxZjDoeY1idiCqaYP0c45mKGSnYXPleJlt[XOnIDjtbZh1fXKnIH;mJGhFSUNzIHHu[EBJTEGFMjmge4l1cCCLQ{WwJI9nKDBwMEGg{txO	NHm0dmYyOjRzOUO4NC=>
HT1080	M4D1RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M2nYRlczKGh?	NHLNcWlFVVOR	NVH1U5hsUUN3ME2yMlQh\|ryP	MlXGNVIzPzBzN{W=
H1299	NYLqRXVSU2mwYYPlJGF{e2G7		MYiyNEBucW5?	MmnMSG1UVw>?	MoDzTY5pcWKrdH;yfUBi[3Srdnn0fUBi\2GrboP0JGhFSUNiZX76fY1mKHerdHigTWM2OCCxZjCwMlE6PCEQvF2=	M4fZbFE1PTJzNEKy
H1299	M{jUWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M2TsR\|czKGh?	MUfEUXNQ	NXXtcmVOUUN3ME23MlI1KM7:TR?=	NEHjT3AyPDV{MUSyNi=>
HeLa	NVS4OG1PU2mwYYPlJGF{e2G7		MVSzNEBucW5?		M3;5[WlvcGmkaYTvdpkh[2:wY3XueJJifGmxbjDh[4FqdnO2IHjpd5RwdmViZHXhZ4V1gWyjc3Wge4l1cCCLQ{WwJI9nKDBwMkig{txO	NEfvXWIyPTZyM{m0PS=>
LOX-IMVI	M4X0Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MU[0PEBp		MmTwTWM2OD1zLkOg{txO	NFjjZXMyPTdzNUS3NC=>
NCI-H226	MojDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHzmcHQ1QCCq		NIHyZZZKSzVyPUKuOkDPxE1?	NHvpR4gyPTdzNUS3NC=>
RXF-631L	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M2HJWFQ5KGh?		MWDJR\|UxRTJizszN	NFnx[HYyPTdzNUS3NC=>
SNB-78	NVP2c5JbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NEK4NlY1QCCq		NHTvd3BKSzVyPUG2JO69VQ>?	NF\je\|MyPTdzNUS3NC=>
St-4	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MWm0PEBp		NFXI[\|hKSzVyPUWuNkDPxE1?	M{m4Z\|E2PzF3NEew
ARP1	M3vLXmZ2dmO2aX;uJGF{e2G7	MlX4NkDPxE1?	MkXROkBp		NGrFOpJKdmS3Y4Tpc44hd2ZiUEKxW2FHOSCpZX7lJIV5eHKnc4Ppc44>	MXKxOFc{PDhyNh?=
CEM	MVnLbY5ie2ViQYPzZZk>		MVGxJIg>	NYXZdFNKTE2VTx?=	M3vpSGlvcGmkaYTpc44hd2ZiSFTBR{B4cXSqIFnDOVAhd2ZiMD6zN{DPxE1?	NWfuN3g{OTZ2MkCwOlQ>
HCT15	NFvPbG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MXK0PEBp		M4fGcWdKPTB;MD64NkDPxE1?	M3q0UFE3PzJ\|MkK3
NCI-H23	NXfpRmp4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MX20PEBp		M1fvfmdKPTB;MD65NkDPxE1?	NV3nR2VDOTZ5MkOyNlc>
GM15850	NVz0XpRmU2mwYYPlJGF{e2G7	NV;zfnpjOi53IN88US=>	NYjVZW1qQTZiaB?=	NY\WS2lnTE2VTx?=	MWrJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5iaHnzeI9v\SCKMzDsfZNqdmViMUSgZYNmfHmuYYTpc44hd2ZiRmjOJIdmdmV?	NWXwR5hQOTZ7MkGzOlc>
GM15850	NVTsVnN5U2mwYYPlJGF{e2G7	MX2yMlUh\|ryP	M2nUV\|k3KGh?	NVfRbndWTE2VTx?=	MoW0TY5pcWKrdHnvckBw\iCKRFHDJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIHjpd5RwdmViSESgcJl{cW6nIEWgZYNmfHmuYYTpc44hd2ZiRmjOJIdmdmV?	MUixOlkzOTN4Nx?=
GM15850	M4XFWGtqdmG\|ZTDBd5NigQ>?	MmSyNk42KM7:TR?=	M1nkS\|k3KGh?	M4rsVGROW09?	NEjGeWhKdmirYnn0bY9vKG:oIFjERWMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDIOEBtgXOrbnWgNVIh[WOndInsZZRqd25ib3[gSnhPKGenbnW=	NULhU4N3OTZ7MkGzOlc>
GM15850	M1L1[2tqdmG\|ZTDBd5NigQ>?	MonkNk42KM7:TR?=	MoHVPVYhcA>?	NEnER2RFVVOR	NInNbGxKdmirYnn0bY9vKG:oIFjERWMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDIN{BtgXOrbnWgPUBi[2W2eXzheIlwdiCxZjDGXG4h\2WwZR?=	MWKxOlkzOTN4Nx?=
GM15850	MkGyT4lv[XOnIFHzd4F6	MVKyMlUh\|ryP	MWW5OkBp	MYrEUXNQ	NWrZOphSUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFQhdHm\|aX7lJFgh[WOndInsZZRqd25ib3[gSnhPKGenbnW=	NXf2XnA1OTZ7MkGzOlc>
GM15850	NXTuPHNMU2mwYYPlJGF{e2G7	M{HrW\|IvPSEQvF2=	NV3PcpIyQTZiaB?=	MnezSG1UVw>?	NVruXGcyUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFQhdHm\|aX7lJFE3KGGlZYT5cIF1cW:wIH;mJGZZViCpZX7l	MoWyNVY6OjF\|Nke=
U937	MoTHSpVv[3Srb36gRZN{[Xl?	NF7FdI82KM7:TR?=	MkjnNlQhcA>?	MX;EUXNQ	MX3D[YxtKGO7Y3zlJIFzemW\|dDDifUBi[2O3bYXsZZRqd25iYYSgV{9IOi:PIIDoZZNm	NGTWbnEyPzByNEexPC=>
H661	NGXac3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NV6xXZZ[PDhiaB?=		M3zmc2lEPTB;MTFOwG0>	Mlm1NVcyPTdyMEm=
U937	NHTvd5VHfW6ldHnvckBCe3OjeR?=	NV\ISGR1PSEQvF2=	NH;GWnkzPCCq	NXfPOFUxTE2VTx?=	M2LkPGlv[3KnYYPlJIlvKGirc4TvcoUhUDNiYXPleJlt[XSrb36=	MX:xO\|Q1Pzd3MB?=
U937	NGCybnlHfW6ldHnvckBCe3OjeR?=	MlrQNUDPxE1?	MoDZNlQhcA>?	MmjUSG1UVw>?	MYfF[oZm[3Rib36gZYxxcGFidIXieYxqdiCjY3X0fYxifGmxbh?=	MUGxO\|Q1Pzd3MB?=
RAW264.7	MoO4SpVv[3Srb36gRZN{[Xl?	MVuxNEDPxE1?	Mlu4NlRp	MVv3ZZRmeg>?	MmfQTY5pcWKrdHnvckBw\iCOUGOtd5RqdXWuYYTl[EBVVk[jbIDoZUBxem:mdXP0bY9vKHerdHigTWM2OCCxZjCwMlc3KM7:TR?=	MVyxO\|Q4PzVzOB?=
RAW264.7	M2XFemZ2dmO2aX;uJGF{e2G7	NYW0ZVU{OTBizszN	NGLRVY8zPGh?	MXv3ZZRmeg>?	M1T6T2lvcGmkaYTpc44hd2ZiTGDTMZN1cW23bHH0[YQhVk9icILv[JVkfGmxbjD3bZRpKEmFNUCgc4YhOS56ODFOwG0>	NHfnUnkyPzR5N{WxPC=>
SC9	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NXTid2ZqPDhiaB?=		NIrZSWlKSzVyPUCuOlA3KM7:TR?=	NGnG[Y4yPzVyN{KxPS=>
ST14A	M33YSGZ2dmO2aX;uJGF{e2G7	MX[1JI5O	NUDwZ4dyPzJiaB?=		NYXTXYFxUW6lcnXhd4UhcW5iUlXTWE9PWlOIIH3SUmEh\XiycnXzd4lwdg>?	NXXNTZJ3OTd3NkW5PVM>
ST14A	M2jWemZ2dmO2aX;uJGF{e2G7	M1j1V\|Uhdk1?	MmTEO\|IhcA>?		NHu3UnhKdmO{ZXHz[UBqdiCHMl[xJI1TVkFiZYjwdoV{e2mxbh?=	MnPTNVc2PjV7OUO=
PANC1	M17NVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1X5NVEh\|ryP			M4HldmlEPTB;MD60OUDPxE1?	M{TLUVE4PTh6N{S0
PANC1	M3i1UWZ2dmO2aX;uJGF{e2G7	M3r5[lEh\|ryP	M{L6TFI1KGh?		M1XZZWlv[3KnYYPlJIlvKHB{MWfBSlEwS0mSMTDn[Y5mKGW6cILld5Nqd25?	NWnESFNjOTd3OEi3OFQ>
PANC1	NXvONm1iTnWwY4Tpc44hSXO\|YYm=	NGrieYoyKM7:TR?=	NHvWfJMzPCCq		Mn;iTY5kemWjc3WgbY4heDJ5a3nwNUBo\W6nIHX4dJJme3Orb36=	M1rRelE4PTh6N{S0
PT45	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mm[0TWM2OD12IN88US=>	Ml7sNVc2QDh5NES=
ACHN	M1ftN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NVWxOWhWOjFiaB?=		NH\nPJdIUTVyPUCuOlUh\|ryP	MYmxO\|Y3OjZyNh?=
PC3	NFv6[YNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NF;Yd2kzOSCq		NV\MRWlOT0l3ME2wMlcyKM7:TR?=	NGfIeJYyPzZ4Mk[wOi=>
A431	NVnhU5R2S3m2b4TvfIlkKEG\|c3H5		MnflO\|IhcA>?		MmGyTWM2OD12LkKg{txO	NFTQV3kyPzZ7MUe2Ny=>
Cal27	M{W3SGN6fG:2b4jpZ{BCe3OjeR?=		MmjlO\|IhcA>?		NGq5SHdKSzVyPUOuNkDPxE1?	MVqxO\|Y6OTd4Mx?=
CCRF-CEM	M{jDWmN6fG:2b4jpZ{BCe3OjeR?=		NIrGXY44OiCq		NF;MOZhKSzVyPUCuPEDPxE1?	M4mxblE4PjlzN{[z
EOL1	MnWzR5l1d3SxeHnjJGF{e2G7		M3X4PFczKGh?		NFfBcVJKSzVyPUGg{txO	MknxNVc3QTF5NkO=
Hec-1-A	M1LQWGN6fG:2b4jpZ{BCe3OjeR?=		NUnWbG1FPzJiaB?=		M37BOWlEPTB;MTFOwG0>	NYnuVI5uOTd4OUG3OlM>
HeLa	MVfLbY5ie2ViQYPzZZk>	MVmxNEDPxE1?	MUmzNEBucW5?	M1TBVGROW09?	NIXMZoRKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JGhFSUNzIIfpeIghUUN3MDDv[kAxNjB{IN88US=>	MYKxO\|Y6OTd4Mx?=
RKOp21	M2nTUGN6fG:2b4jpZ{BCe3OjeR?=		M2f5c\|czKGh?		MYHJR\|UxRTFwN{[g{txO	MX6xO\|Y6OTd4Mx?=
Saos2	M4HKe2N6fG:2b4jpZ{BCe3OjeR?=		MYW3NkBp		Mlf2TWM2OD1{LkOg{txO	MkjrNVc3QTF5NkO=
SK-OV-3	MXjDfZRwfG:6aXOgRZN{[Xl?		M4PrRVczKGh?		Mmf3TWM2OD1{LkKg{txO	NUL5eHZbOTd4OUG3OlM>
U87MG	NFTOU\|JEgXSxdH;4bYMhSXO\|YYm=		NF3p[pQ4OiCq		MoLYTWM2OD1zMTFOwG0>	NI\RVGoyPzZ7MUe2Ny=>
NUGC3	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2fjdFUh\|ryP	MmLHNlQhcA>?		NXTFUFBnT0l3ME2yMlc6KM7:TR?=	NHSyPHcyPzlyNEi0Ny=>
CCD1059SK	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{Szd2lEPTB;NEOuOUDPxE1?	MnHGNVgzPDd3NUS=
HepG2	NF7vOXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{jNfmlEPTB;MD6wNFA3KM7:TR?=	MYOxPFI1PzV3NB?=
HT1080	NGjPRWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml3CTWM2OD1yLkCwNlQh\|ryP	MVKxPFI1PzV3NB?=
SKBR3	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1fpc2lEPTB;MD64JO69VQ>?	MkPSNVgzPDd3NUS=
SNB78	NF3WPZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4\vTGVEPTB;MU[g{txO	NHriRVMyQDJ2N{W1OC=>
SQ20B	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVjJR\|UxRTNizszN	NV\pT2M2OTh{NEe1OVQ>
St4	NVqxXWtZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmH2SWM2OD13LkKg{txO	MUSxPFI1PzV3NB?=
MCF7	NYLu[FRVTnWwY4Tpc44hSXO\|YYm=	NYHKemZtOTBizszN	NVjlc4p{QCCq	NWLxXYJYTE2VTx?=	M{T5[Wlv\HWldHnvckBw\iC2dXL1cIlvKGi7cHXyZYNmfHmuYYTpc44>	M{HFSVE5OjZ7MkK2
HEK293	NX;hUJdFU2mwYYPlJGF{e2G7		NFSyZmwyKGh?	MYXEUXNQ	MYHJcohq[mm2aX;uJI9nKEiGQVOxJJdqfGhiSVO1NEBw\iByLkCzJO69VQ>?	NY\mdGt[OTh\|MEi1OlM>
HEK293	NFW0fWxMcW6jc3WgRZN{[Xl?		NG\5[HgyKGh?	NFK1VGlFVVOR	MYnJcohq[mm2aX;uJI9nKEiGQVOzJJdqfGhiSVO1NEBw\iByLkC1O{DPxE1?	MV6xPFMxQDV4Mx?=
G401	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Ml\CO\|IhcA>?	M{nTOGROW09?	M1rmS2lEPTB;MTFOwG0>	MmH4NVg{PzB\|N{O=
HeLa	M4W0Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MVW3NkBp	MUTEUXNQ	NWLmSm9yUUN3ME2wMlQ3KM7:TR?=	MYOxPFM4ODN5Mx?=
Human renal epithelial cell	NWLLV4JnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3jwOFczKGh?	M{DiZWROW09?	M{KzVmlEPTB;MUSg{txO	MX6xPFM4ODN5Mx?=
U937	NI\rb5lHfW6ldHnvckBCe3OjeR?=	Mn:3OUDPxE1?	NF:yXFEzPCCq		MVXJcoR2[3Srb36gc4YhcGm\|dH;u[UBJPCCqeYDldoFk\XS7bHH0bY9v	MVyxPFM5OTJ\|OB?=
U937	M4ftcmZ2dmO2aX;uJGF{e2G7	M12wdVUh\|ryP	M1H2Z\|I1KGh?		MXXJcoR2[3Srb36gc4Yh[WyyaHGgeJVjfWyrbjDofZBmemGlZYT5cIF1cW:w	NH\2NI8yQDN6MUKzPC=>
U937	NGL3[YpHfW6ldHnvckBCe3OjeR?=	NI[wenc2KM7:TR?=	MUmyOEBp		NH3HTGdKdmS3Y4Tpc44hd2ZicEKxJIV5eHKnc4Ppc44>	M2TkPVE5OzhzMkO4
U937	NGnSSI9HfW6ldHnvckBCe3OjeR?=	NVq5cY5[PSEQvF2=	NXv2U\|FzOjRiaB?=		M2G5XWlv\HWldHnvckBw\iCjcH;weI9{cXN?	NXjrWpdVOTh\|OEGyN\|g>
U937	MYXGeY5kfGmxbjDBd5NigQ>?	MWO1JO69VQ>?	NWj5[JdKOjRiaB?=		M4r5eGlv\HWldHnvckBw\iCpcnHueYxw[3m2aXOg[Iln\mW{ZX70bYF1cW:w	NFv2OWwyQDN6MUKzPC=>
U937	NFjEe4RMcW6jc3WgRZN{[Xl?	NELlS4I2KM7:TR?=	MnfaNlQhcA>?		NVjD[Gl2UW6qaXLpeIlwdiCxZjDoeY1idiCKRFHDNS=>	NIXkdGUyQDN6MUKzPC=>
U937	MkmzT4lv[XOnIFHzd4F6	MUS1JO69VQ>?	NWPVW5RPOjRiaB?=		NVrmOGpRUW6qaXLpeIlwdiCxZjDoeY1idiCKRFHDOC=>	MWixPFM5OTJ\|OB?=
HEK-TE	NGf3RnRHfW6ldHnvckBCe3OjeR?=	MYq1JO69VQ>?	MXK2bC=>	NGrmRpdFVVOR	Mn7ZTY5kemWjc3WgbY4hcGm\|dH;u[UBJOyCjY3X0fYxifGmxbh?=	M3zNelE5PDN2MUS0
HPDE6c7	NEnWVZVEgXSxdH;4bYMhSXO\|YYm=	MWW1NEDPxE1?	MWe3NkBp	MnnhSG1UVw>?	Ml7UTWM2OD1zLkOg{txO	M2nwXFE5PDl2NE[z
Human microvascular epithelial cell	NFXndJhEgXSxdH;4bYMhSXO\|YYm=	NFvxZo02OCEQvF2=	MofPO\|IhcA>?	MVHEUXNQ	M4\yOWlEPTB;MT6zJO69VQ>?	NHnpVpAyQDR7NES2Ny=>
Hup T3	MX3DfZRwfG:6aXOgRZN{[Xl?	NYXLe3F1PTBizszN	MWS3Nog>	MYDEUXNQ	Mm\nTWM2OD1yLkig{txO	MXexPFQ6PDR4Mx?=
Mia Paca2	M{P1UmN6fG:2b4jpZ{BCe3OjeR?=	M1PmPFUxKM7:TR?=	NV[wdm9KPzKq	M1HpfGROW09?	NGfodmpKSzVyPUGuNUDPxE1?	M4PPfVE5PDl2NE[z
Panc 04.03	MojRR5l1d3SxeHnjJGF{e2G7	NV[1[m55PTBizszN	M3flblczcA>?	NF;0UmZFVVOR	M2DqUmlEPTB;MT6yJO69VQ>?	NVS2VXd1OTh2OUS0OlM>
SU 86.86	MmHSR5l1d3SxeHnjJGF{e2G7	M2DTSlUxKM7:TR?=	NYjGcYZ7PzKq	NUj3WJV{TE2VTx?=	NFrhd3FKSzVyPUGuN{DPxE1?	M4TtR\|E5PDl2NE[z
HEK293	NVHjfnJ6U2mwYYPlJGF{e2G7		MoG3N{Bp		M1HpVGlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgTGRCSzZiZYjwdoV{e2mxbjD3bZRpKEmFNUCgc4YhOC5yMUmg{txO	NX;XfY81OTh3NUi2Olk>
HeLa	Mmj1T4lv[XOnIFHzd4F6		NWDFToY2OiCq		NUm5PHJqUW6qaXLpeIlwdiCxZjDueYNt\WG{IFjERWMhf2m2aDDJR\|UxKG:oIECuNFg{KM7:TR?=	NV\3NHduOTh3NUi2Olk>
RAW264.7	MVrGeY5kfGmxbjDBd5NigQ>?	MlHDNkDPxE1?	M1XwdVMvPSCq	NYDpeoFUTE2VTx?=	MkP3RY51cW2jbHHybYFtKGGldHn2bZR6KGGpYXnud5QhWGyjc33v[Il2dSCoYXzjbZBienWvIHnu[oVkfGWmIIfpeIghUUN3MDDv[kAxNjFzIN88US=>	NEmwV28yQDZ2NEm2PS=>
NB4			M1nMVFQ5cA>?	NGHubplFVVOR	NVLzW41jUUN3ME2wMlYh\|ryP	NGjGOIIyQDd{M{O0PS=>
HEK293	NHH0[2JHfW6ldHnvckBCe3OjeR?=	NFe5c2kyOCEQvF2=	Ml\hNlQhcA>?	MkfySG1UVw>?	NHvaTpZC[3SrdnH0bY9vKG:oIH3veZNmKFewdEPhJJNq\26jbHnu[{BmgHC{ZYPz[YQ>	M1fzPVE6ODJ{Nke1
HCT116	NWfhXXc3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MV23Nog>	NWjXWoJDTE2VTx?=	Ml\rTWM2OD1yLkOxJO69VQ>?	MkX4NVkxQDR{OUS=
HeLa	MlvCT4lv[XOnIFHzd4F6	NInZRpQzKM7:TR?=	NVrCc444OzBibXnu	NGLqOXJFVVOR	M3\HOmlvcGmkaYTpc44hd2ZiSFTBR\|IhcW5iaIXtZY4hUGWOYTDj[YxteyC5aYToJGlEPTBib3[gNE4yKM7:TR?=	NH\lflQyQTB6NEK5OC=>
IGROV1	MnLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M2\ZW\|czKGh?	MnniSG1UVw>?	NHGxZlZKSzVyPUKuNkDPxE1?	M1e3NlE6ODh2Mkm0
IGROV1	NH7PUlNMcW6jc3WgRZN{[Xl?	Mo[2OUDPxE1?	NID1coYzPCCq	NH[zc4tFVVOR	Ml7STY5pcWKrdHnvckBw\iCKRFHDJIF{e2W\|c3XkJIF{KHB3MzDhZ4V1gWyjdHnvci=>	NFXUOGIyQTB6NEK5OC=>
IGROV1	MmPlT4lv[XOnIFHzd4F6	MUmxNEDPxE1?	NW\O[Yw6PCCq	MVnEUXNQ	MmfuTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W\|c3XkJIF{KGirc4TvcoUuUDRiYXPleJlt[XSrb36=	MYSxPVA5PDJ7NB?=
IGROV1	NHzCfJFMcW6jc3WgRZN{[Xl?	M1q0N\|ExKM7:TR?=	NXfLbGt7PCCq	NXz3ToZpTE2VTx?=	NHnYZYhKdmirYnn0bY9vKG:oIFjERWM3KGG\|c3Xzd4VlKGG\|IHHsdIhiNXS3YoXsbY4h[WOndInsZZRqd25?	NX3wUoprOTlyOESyPVQ>
T24	NH\lW4dMcW6jc3WgRZN{[Xl?		NW\mN5hOOyCq		NFrOWVFKdmS3Y4Tpc44hd2ZiaHnzeI9v\SCKMzDhZ4V1gWyjdHnvckB4cXSqIFXDOVAhd2ZiMD6xNkDPxE1?	NIXPWIkyQTB6NEO5OS=>
T24	M3;SRWtqdmG\|ZTDBd5NigQ>?		M{PzU\|MhcA>?		MV7JcoR2[3Srb36gc4Yh[WyyaHGgeJVjfWyrbjDhZ4V1gWyjdHnvckB4cXSqIFXDOVAhd2ZiMD6yOUDPxE1?	Ml3MNVkxQDR\|OUW=
HeLa	NUDiPVFJU2mwYYPlJGF{e2G7		MUCxOUBucW5?	MmfXSG1UVw>?	NWjTZo4yUW6qaXLpeIlwdiCxZjDISGFEPiCocn;tJI52[2ynYYKg[Zh1emGldDD3bZRpKEmFNUCgc4YhOC5yOEW1JO69VQ>?	MU[xPVA6Ozh6NB?=
HeLa	MoDKT4lv[XOnIFHzd4F6		NWjObnRmOTVibXnu	NGTmTlZFVVOR	MXnJcohq[mm2aX;uJI9nKEiGQVO4JIZzd21iboXjcIVieiCneITyZYN1KHerdHigTWM2OCCxZjCxMlg3KM7:TR?=	MlnBNVkxQTN6OES=
NCI-H69	NXf1b2s2S3m2b4TvfIlkKEG\|c3H5		NHHSOnk4OiCq	M{judGROW09?	M2KyTmlEPTB;Mj6wOkDPxE1?	M1nITVE6ODl\|OEi0
SKMES1	M4TKV2N6fG:2b4jpZ{BCe3OjeR?=		NV34[ZZ7PzJiaB?=	MluySG1UVw>?	NVy0b2xRUUN3ME2yMlQzKM7:TR?=	NWD2cJJqOTlyOUO4PFQ>
S2	MULLbY5ie2ViQYPzZZk>	M4XieFAvOS1zMDFOwG0>	MXixJIg>		MX7Jcohq[mm2aX;uJI9nKFCuYYPtc4RqfW1iZnHsZ4lx[XK3bTDISGFEOSCneIDy[ZN{\WRid3n0bEBKSzVyIH;mJFAvODV7IN88US=>	MVKxPVMyPzR3MB?=
SHSY5Y	NETU[HpMcW6jc3WgRZN{[Xl?	MVWxNEDPxE1?	M3jvVlQ5KGh?	MV;EUXNQ	M4jBXmlvcGmkaYTpc44hd2ZiSFTBR{B4cXSqIFnDOVAhd2ZiMD61JO69VQ>?	M1PyWVE6OzR2MUe1
SHSY5Y	MWPDfZRwfG:6aXOgRZN{[Xl?	M163cFExKM7:TR?=	M4TUUlQ5KGh?	M{X3VWROW09?	M1\OSGlEPTB;MjFOwG0>	Mom3NVk{PDRzN{W=
DMS114	NX7L[XJNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1K4ZlQ5KGh?		NILPUo1IUTVyPUKuPUDPxE1?	NYLmdnA5OTl2MUmyNFU>
HBC5	NYT0dYRJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3v0bFQ5KGh?		NU\HNJBCT0l3ME2xO{DPxE1?	M3WyO\|E6PDF7MkC1
SNB78	NIXu[IhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NIO5W5Y1QCCq		NF;KdplIUTVyPUG2JO69VQ>?	M4X0VVE6PDF7MkC1
HeLa	Mk\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M2rMeVczKGh?	NF[2N5VFVVOR	M2nmR2lEPTB;MD60OkDPxE1?	NETDSVUyQTR2MUi0Oi=>
BHK	NFLwWVJMcW6jc3WgRZN{[Xl?	MXu1JO69VQ>?	MnzJNlQhcA>?	Mkf4SG1UVw>?	M1u0OWlvcGmkaYTpc44hd2ZiSFTBR\|ch\XiycnXzd4VlKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJJBt[XOvYTDt[Y1jemGwZTDG[IVtfGF3MEigR2ZVWiCycn;0[Ylv	MV[xPVk3Pjd6OR?=
CFBE41o-	MVnLbY5ie2ViQYPzZZk>	M3LnRVUh\|ryP	M2TYZVghcA>?	MXjEUXNQ	MlPWTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W\|c3XkJIF{KGi7cHXyZYNmfHmuYYTpc44hd2ZiaHnzeI9v\SCKMx?=	MXmxPVk3Pjd6OR?=
CFBE41o-	M4H1VGtqdmG\|ZTDBd5NigQ>?	NHHaW4g2KM7:TR?=	NGTLb441KGh?	MVTEUXNQ	NI\KNYlKdmirYnn0bY9vKG:oIFjERWMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gcZV1[W62IF\k[Yx1[TVyODDDSnRTKHC{b4TlbY4hdGW4ZXy=	NUHqSJg4OTl7Nk[3PFk>
CFBE41o-	NFu3dmpMcW6jc3WgRZN{[Xl?	M3nvUVEh\|ryP	NV7MZoRMOSCq	NHrUPHVFVVOR	NXm5c3lkUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJGNHXFJicILveIVqdiCuZY\lcC=>	MV6xPVk3Pjd6OR?=
Primary bronchial epithelial cell	M32zeGtqdmG\|ZTDBd5NigQ>?	MknUNUDPxE1?	MlS3NlQhcA>?	MUXEUXNQ	NECyU2NKdmirYnn0bY9vKG:oIFjERWM4KGG\|c3Xzd4VlKGG\|IHnu[JVkfGmxbjDv[kBufXSjboSgSoRmdHSjNUC4JGNHXFJicILveIVqdiCjcHnjZYwhe3W{ZnHj[UBtd2OjbHn6ZZRqd25?	M1LTSFE6QTZ4N{i5
CFBE41o-	NEXIXWVMcW6jc3WgRZN{[Xl?	MUWxJO69VQ>?	MnXLOUBl[Xm\|	M4LT[mROW09?	MnnMTY5pcWKrdHnvckBw\iCKRFHDO{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDzeIFjcWyrenH0bY9vKG:oIF\k[Yx1[TVyODDDSnRTKHC{b4TlbY4>	MlLoNVk6PjZ5OEm=
CFBE41o-	M{PP[WtqdmG\|ZTDBd5NigQ>?	NGnQRmQyKM7:TR?=	Mn;CNlQhcA>?	M1\TR2ROW09?	M3Poe2lvcGmkaYTpc44hd2ZiSFTBR\|ch[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gSoRmdHSjNUC4JGNHXFJicILveIVqdiC2cnHm[olkc2mwZx?=	NHrqZnAyQTl4Nke4PS=>
CFBE41o-	MWjLbY5ie2ViQYPzZZk>	MVW1JO69VQ>?	NHzZOGczPCCq	NF3mbWJFVVOR	NEjSS\|lKdmirYnn0bY9vKG:oIFjERWM4KGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJJJifGVib3[gcYF1fXKjdHnvckBw\iCFRmTSJJBzd3SnaX6geI8hcXS\|IHfsfYNw\m:{bR?=	NVPtVHJGOTl7Nk[3PFk>
CFBE41o-	MYTLbY5ie2ViQYPzZZk>	NGL4cmI2KM7:TR?=	MknYNlQhcA>?	NHfseldFVVOR	NHHOfIxKdmirYnn0bY9vKG:oIFjERWM4KGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJJN1[WKrbHn0fUBw\iCIZHXseIE2ODhiQ1\UVkBxem:2ZXnu	MYqxPVk3Pjd6OR?=
CFBE41o-	NEHiS5FMcW6jc3WgRZN{[Xl?	MlnOOUDPxE1?	MVeyOEBp	NEHING9FVVOR	MoLrTY5pcWKrdHnvckBw\iCKRFHDO{Bie3Onc4Pl[EBieyClb4Ly[YN1cW:wIH;mJI12fGGwdDDG[IVtfGF3MEigR2ZVWiC2cnHm[olkc2mwZzD0c{Bk\WyuIIP1doZi[2ViYYOg[4x6[2:ob4Lt	Mmi1NVk6PjZ5OEm=
Primary bronchial epithelial cell	M1LUNWtqdmG\|ZTDBd5NigQ>?	NV3ZenVvPSEQvF2=	Ml\hNlQhcA>?	NEDUfWJFVVOR	NVXyWmdnUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHnu[JVkfGmxbjDv[kBufXSjboSgSoRmdHSjNUC4JGNHXFJicILveIVqdiCjcHnjZYwhe3W{ZnHj[UBtd2OjbHn6ZZRqd25?	NEjoXGgyQTl4Nke4PS=>
Primary bronchial epithelial cell	MmfNT4lv[XOnIFHzd4F6	MoewNUDPxE1?	MWG5OkBp	M1TaTmROW09?	MlTTTY5pcWKrdHnvckBw\iCKRFHDO{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDzbI9zfCClaYLjeYl1KGO3coLlcpR{	MoHhNVk6PjZ5OEm=
BxPC3	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1jnOFczKGh?		NHjPd5pKSzVyPUKuO{DPxE1?	MXGyNFE1Ozd5OB?=
CAL27	MlHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MmTmO\|IhcA>?		MXvJR\|UxRTNwN{Kg{txO	M{DobFIxOTR\|N{e4
Capan1	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NX[5OIZqPzJiaB?=		NIjiW3VKSzVyPUeuN{DPxE1?	MUmyNFE1Ozd5OB?=
HCC827	M1LrbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M3zRdVczKGh?		NWn2WG44UUN3ME2xMlgh\|ryP	NVTUZYxZOjBzNEO3O\|g>
LNCAP	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Ml71O\|IhcA>?		MYHJR\|UxRTBwNUig{txO	MViyNFE1Ozd5OB?=
NCI-H2122	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MlP4O\|IhcA>?		NVrOcm9iUUN3ME23MlUh\|ryP	NHe3ZpYzODF2M{e3PC=>
NCI-H358	M1TkWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MoOyO\|IhcA>?		Mni2TWM2OD1{LkWg{txO	NWD0XpRuOjBzNEO3O\|g>
SCC15	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NEf6UI84OiCq		NXPkS5c1UUN3ME2yMlQ6KM7:TR?=	MVyyNFE1Ozd5OB?=
SCC25	MkfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NWLET2pEPzJiaB?=		M4\1TWlEPTB;MT65N{DPxE1?	Mk\JNlAyPDN5N{i=
SKHEP1	NIDZfmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MmDDO\|IhcA>?		M2f2W2lEPTB;Mz60OkDPxE1?	NYX3VGVTOjBzNEO3O\|g>
BJ	NFzrSFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkPaNVAxKM7:TR?=	NYrUR4VEPDhiaB?=	Ml\ESG1UVw>?	NUjYcZpGT3Kxd4ToJIlvcGmkaYTpc44h[XRiMD6wOUB1dyBzMECgeW0>	NYXIdINpOjBzNEO4OFA>
MUF	NUjtU4hnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWPVbHRIOTByIN88US=>	MofDOFghcA>?	M3naZmROW09?	MVHHdo94fGhiaX7obYJqfGmxbjDheEAxNjB3IITvJFExOCC3TR?=	NGr4PFEzODF2M{i0NC=>
Caco-2	NWTEblRLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWWxNFAh\|ryP	MmHlOFhp	MUTEUXNQ	Mo[zTWM2OD16LkGg{txO	M{PsPVIxOTR\|OESw
Caco-2	M2jPVGtqdmG\|ZTDBd5NigQ>?	NXvFTWM2PSEQvF2=	NXP2OlE4PCCq	NV;D[YpRTE2VTx?=	MUDJcoR2[3Srb36gc4YhUESDQz3t[YRq[XSnZDDobZN1d26nIHHj[ZR6dGG2aX;uJGlEPTBib3[gNE4xOzdizszN	NIDvUY0zODF2M{i0NC=>
Caco-2	MlvuT4lv[XOnIFHzd4F6	MoK0NE4{OTZibl2geI8hOzFwNjFOwG0>	M{nHSlQhcA>?	MXLEUXNQ	MkHQSZghfmm4bzDpcohq[mm2aX;uJI9nKGi3bXHuJGhFSUNzIIfpeIghUUN3MDDv[kAxNjFzOTFOwG0>	M3XRc\|IxOTR\|OESw
Caco-2	NVTGTIdiU2mwYYPlJGF{e2G7	Mn6xNE4{OTZibl2geI8hOzFwNjFOwG0>	NHn6bnE1KGh?	NUPHT2x6TE2VTx?=	M3rFS2V5KH[rdn:gbY5pcWKrdHnvckBw\iCqdX3hckBJTEGFMzD3bZRpKEmFNUCgc4YhOC5zNEeg{txO	M2HWfVIxOTR\|OESw
Caco-2	NFHaWoJMcW6jc3WgRZN{[Xl?	NET0Xm83NjN{IH7NJJRwKDZ\|MjFOwG0>	M{nCW\|QhcA>?	M4TWVmROW09?	MXnFfEB3cX[xIHnubIljcXSrb36gc4YhcHWvYX6gTGRCSzVid3n0bEBKSzVyIH;mJFEzNjZizszN	Mn\FNlAyPDN6NEC=
Caco-2	NET6e5NMcW6jc3WgRZN{[Xl?	MoO0Ok4{OiCwTTD0c{A3OzJizszN	MlPXOEBp	NVrnRmVFTE2VTx?=	NXnQOno3TXhidnn2c{BqdmirYnn0bY9vKG:oIHj1cYFvKEiGQVO3JJdqfGhiSVO1NEBw\iB2MTFOwG0>	MXmyNFE1Ozh2MB?=
Caco-2	NGDI[pVMcW6jc3WgRZN{[Xl?	NGG5fnMxNjNzNjDuUUB1dyB\|MT62JO69VQ>?	NUnsSJBvPCCq	NX3tT2ozTE2VTx?=	NGLTNlFGgCC4aY\vJIlvcGmkaYTpc44hd2ZiaIXtZY4hUESDQ{[=	M3nSeFIxOTR\|OESw
HepG2	NHj5Z4xMcW6jc3WgRZN{[Xl?	MoDkOUDPxE1?	NVfHd3BFPmh?	Mm\sSG1UVw>?	Mk\ZTY5lfWO2aX;uJI9nKEiGQVOtcYVlcWG2ZXSgbIl{fG:wZTDhZ4V1gWyjdHnvci=>	Mkn3NlAyPDN6NEC=
HepG2	NEjkdWxMcW6jc3WgRZN{[Xl?	MofPOUDPxE1?	MlezOog>	MXrEUXNQ	M{DKZmlv\HWldHnvckBw\iCKRFHDMY1m\GmjdHXkJIhqe3SxbnWgbJlx\XKjY3X0fYxifGmxbh?=	M4OySFIxOTR\|OESw
HepG2	NVnUN\|V1U2mwYYPlJGF{e2G7	NXvoNoxTPSEQvF2=	MnvXOog>	MorQSG1UVw>?	NGmzfIVKdmS3Y4Tpc44hd2ZiSFTBR{1u\WSrYYTl[EBidHCqYT30eYJ2dGmwIHHj[ZR6dGG2aX;u	M{HxVlIxOTR\|OESw
HepG2	M2fsRmtqdmG\|ZTDBd5NigQ>?	NFny[IM2KM7:TR?=	MojIOog>	M3G2SGROW09?	MYrJcoR2[3Srb36gc4YhUESDQz3t[YRq[XSnZDDIN{9JPCCqaYP0c45mKGGlZYT5cIF1cW:w	MWeyNFE1Ozh2MB?=
COLO205	Mn;jT4lv[XOnIFHzd4F6	MYGxNEDPxE1?	NXHISoI5OjRiaB?=	MUHEUXNQ	MUnJcohq[mm2aX;uJI9nKEiGQVOxJIF{e2W\|c3XkJIF{KGmwZIXjeIlwdiCxZjDobZN1d26nIFizJIFk\XS7bHH0bY9vKHerdHigTWM2OCCxZjCyMlIh\|ryP	MYOyNFQ2OTN5OB?=
SCC4	MkDrT4lv[XOnIFHzd4F6	NUDpTIJEOSEQvF2=	MXyyOIg>		NX\z[2ZpUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJJR2[nWuaX6gZYNmfHmuYYTpc44>	M{f3[FIxPDV{MkK1
SCC4	Mnr2T4lv[XOnIFHzd4F6	Mlr4NUDPxE1?	MmK3NlRp		NHTDbllKdmirYnn0bY9vKG:oIFjERWMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDhZ4V1gWyjdHnvci=>	NXzyUoxWOjB2NUKyNlU>
SCC4	NFHRRnlHfW6ldHnvckBCe3OjeR?=	NIXxblgyKM7:TR?=	MlXlOUBucW5?		MULB[49vcXO2IHHjeIl3cXS7IHH0JHZFWiCjc4Pld5Nm\CCjczDpcoR2[3Srb36gc4YhS1mSMkSg[4Vv\SCneIDy[ZN{cW:w	Mk\mNlA1PTJ{MkW=
NB4	NUjaZnZoTnWwY4Tpc44hSXO\|YYm=	NU\xeIVZPSEQvF2=	MoPKNlQhcA>?	M2jFcmROW09?	NEjReGZE\WyuIHP5Z4xmKGG{cnXzeEBie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDhZ4N2dXWuYYTpc44h[XRicILlMWcyKHCqYYPl	MkjINlA1QTF2NEC=
NB4	MljHT4lv[XOnIFHzd4F6	NWTqNnNGPSEQvF2=	NIntPWEzPCCq	Mlu4SG1UVw>?	M2n5cmlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDhZ4V1gWyjdHWgeJVjfWyrbjDs[ZZmdA>?	M4\5UlIxPDlzNESw
NB4	NYTRSIxSTnWwY4Tpc44hSXO\|YYm=	NVLxcHI3PSEQvF2=	M3PubVI1KGh?	MknuSG1UVw>?	M17OcGlv\HWldHnvckBw\iCyMkHXRWYyN0OLUEGg[ZhxemW\|c3nvci=>	MV6yNFQ6OTR2MB?=
NB4	NXjNTG5tU2mwYYPlJGF{e2G7	MVu1JO69VQ>?	MVeyOEBp	Ml7nSG1UVw>?	MVnJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5iaHnzeI9v\SCKMzDhZ4V1gWyjdHnvci=>	MV2yNFQ6OTR2MB?=
NUGC3	NEnNb5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFK5VGtIUTVyPUKuPVQh\|ryP	NYDRWJlpOjB6NUC5O\|E>
A549	NIXxeXdHfW6ldHnvckBCe3OjeR?=	M1n4T\|Uh\|ryP	NXK4fGdpOyCq	MW\EUXNQ	NVz5W2s5UW6mdXP0bY9vKG:oIHH1eI9xcGGpeTDpckBpfW2jbjDBOVQ6KGOnbHzzJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIFzDN2lK	NGfsNW4zODh3NUKwPC=>
HUT78	M2LVb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NHfpXWQ4OiCq	M4LYbmROW09?	MULHTVUxRTBwMzFOwG0>	MnjsNlA5QDR{MEi=
U937	M3nwOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MVe3NkBp	NWnyS4t1TE2VTx?=	M1jwNmdKPTB;MD6zPUDPxE1?	NVm1Z2dJOjB6OESyNFg>
A431	NInIOoZEgXSxdH;4bYMhSXO\|YYm=		NFvqZZY4OiCq		NH3kZnFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCPDNzIHPlcIx{KG:4ZYLlfJBz\XO\|aX7nJGVITlJid3n0bEBKSzVyIH;mJFQvOiEQvF2=	MmDFNlExQDB4Mkm=
A549	NYXvc2hGS3m2b4TvfIlkKEG\|c3H5		MkDSO\|IhcA>?		M37ySWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMhd3[ncnX4dJJme3OrbnegTGRCSyC5aYToJGlEPTBib3[gNU45KM7:TR?=	NFnDNlEzOTB6ME[yPS=>
CAL27	M1PyW2N6fG:2b4jpZ{BCe3OjeR?=		NX\qbYpOPzJiaB?=		NFfhWlZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBESUx{NzDj[YxteyCxdnXy[ZhxemW\|c3nu[{BGT0[UIIfpeIghUUN3MDDv[kA{NjJizszN	NELXOXUzOTB6ME[yPS=>
HeLa	MXvDfZRwfG:6aXOgRZN{[Xl?		M2HE[lczKGh?		MkS5R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVN[SClZXzsd{BwfmW{ZYjwdoV{e2mwZzDISGFEKHerdHigTWM2OCCxZjCxMlUh\|ryP	NW\SdG1qOjFyOEC2Nlk>
Sf21	NY\hbFVlU2mwYYPlJGF{e2G7		NFfYXnM{KGh?		M3zZXWlvcGmkaYTpc44hd2ZiRnzh[{B1[WepZXSgbJVu[W5icnXjc41jcW6jboSgTGRCSzhiZYjwdoV{e2WmIIfpeIghUUN3MDDv[kAyNjJizszN	M3Ty[VIyODhyNkK5
SKBR3	NETPPZdEgXSxdH;4bYMhSXO\|YYm=		NUjDW3F7PzJiaB?=		NHjSSFNEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUU0KUMzDj[YxteyCxdnXy[ZhxemW\|c3nu[{BJTVJ{IIfpeIghUUN3MDDv[kAzNjZizszN	NWTrV3l1OjFyOEC2Nlk>
SKOV3	Ml;sR5l1d3SxeHnjJGF{e2G7		MlfyO\|IhcA>?		MlP2R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV2tQXjNiY3XscJMhd3[ncnX4dJJme3OrbnegTGVTOiC5aYToJGlEPTBib3[gNk4zKM7:TR?=	M1vaelIyODhyNkK5
COR-L23	MoLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnP6NVAh\|ryP	MXm3NkBp	NE\5UHFFVVOR	MVvHTVUxRTFwMTFOwG0>	NULPOXRkOjFyOEC2OFc>
DU145	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1HmSlExKM7:TR?=	MUm3NkBp	MXnEUXNQ	NETaNpJIUTVyPUGuNFUh\|ryP	M{m5c\|IyODhyNkS3
LoVo	M{ntc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV;oNGp2OTBizszN	MoPXO\|IhcA>?	NHrJV4xFVVOR	M2C0TmdKPTB;MT63JO69VQ>?	MkC1NlExQDB4NEe=
MCR5-SV2	NYTZdXNLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF3mSZMyOCEQvF2=	NFv0XFU4OiCq	M1K0[GROW09?	MYDHTVUxRTJwMTFOwG0>	MWCyNVA5ODZ2Nx?=
HCT116	M3O5UmtqdmG\|ZTDBd5NigQ>?	NWrzZmhyOzBizszN	M2HLNVMxKGh?	MWXEUXNQ	MVHJcohq[mm2aX;uJI9nKEiGQVO2JIF{e2W\|c3XkJIF{KGmwZIXjeIlwdiCxZjDhcJBp[S22dXL1cIlvKGGlZYT5cIF1cW:w	Ml7INlExQDB4NEe=
HCT116	M3H2[mtqdmG\|ZTDBd5NigQ>?	NGO2NXY{OCEQvF2=	NUf1VpoxOzBiaB?=	MXPEUXNQ	NVzsZWdPUW6qaXLpeIlwdiCxZjDISGFEOSCjc4Pld5Nm\CCjczDpcoR2[3Srb36gc4YhcGm\|dH;u[UBJO0t7IHHj[ZR6dGG2aX;u	NXX2eJdZOjFyOEC2OFc>
U937	MW\LbY5ie2ViQYPzZZk>	NEf5VVA2KM7:TR?=	MkTPNlQhcA>?	NEiwenFFVVOR	NFTVZXhKdmirYnn0bY9vKG:oIHjpd5RwdmViYXPleJltfHKjboPm[ZJie2ViYYPz[ZN{\WRiYYOgbY5kemWjc3Wgc4Yh[WOndInsZZRqd25ib3[gbIl{fG:wZTDIN{BifCCNOR?=	M{fpcVIyOjl{NEmy
U937	MoXvT4lv[XOnIFHzd4F6	M3rzc\|Uh\|ryP	NETpNGczPCCq	MVzEUXNQ	NG\oW\|lKdmirYnn0bY9vKG:oIHjpd5RwdmViYXPleJltfHKjboPm[ZJie2ViYYPz[ZN{\WRiYYOgbY5kemWjc3Wgc4Yh[WOndInsZZRqd25ib3[gbIl{fG:wZTDIN{BifCCNMUi=	MXSyNVI6OjR7Mh?=
U937	NIG4bmNMcW6jc3WgRZN{[Xl?	NHLrTVc2KM7:TR?=	NUHmSZVxOjRiaB?=	NGfEdGxFVVOR	NGXBeHJKdmirYnn0bY9vKG:oIHjpd5RwdmViYXPleJltfHKjboPm[ZJie2ViYYPz[ZN{\WRiYYOgbY5kemWjc3Wgc4YheGGwLXHj[ZR6dGG2ZXSgbIl{fG:wZTDIOEBt\X[nbB?=	MYWyNVI6OjR7Mh?=
U937	MUDLbY5ie2ViQYPzZZk>	NWTpToR5PSEQvF2=	NHexbHMyPSCvaX6=	MWLEUXNQ	NYjlSodPUW6qaXLpeIlwdiCxZjDobZN1d26nIHHj[ZR6dHS{YX7z[oVz[XOnIHHzd4V{e2WmIHHzJIlv[3KnYYPlJI9nKGirc4TvcoUhUDNiYXPleJlt[XSrb36gcIV3\Wx?	MmG0NlEzQTJ2OUK=
A2780	NHrBdnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NVfJU4N2QTZiaB?=	NEfyZXlFVVOR	NYr0Z3pOUUN3ME2xMlYzKM7:TR?=	MXOyNVY{PDR\|MB?=
COLO205	NXPqcG5GT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NGjjTmo6PiCq	NWm2[3FYTE2VTx?=	NVjXOmFGUUN3ME2yMlEzKM7:TR?=	NX3USGh6OjF4M{S0N\|A>
Hep3B	M2jUeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXjXWoplPDhiaB?=	NWX3VY9xTE2VTx?=	NG\KXlhIUTVyPUGuNlEh\|ryP	M2HWSlIyPzF{MUS2
GM11272	NYXPb2FmTnWwY4Tpc44hSXO\|YYm=	Mmm4NVAxKG6P	MYm3NkBp	NWTve2R{TE2VTx?=	M{HGWXJm[WO2aY\heIlwdiCxZjDN[WNxOiCvdYThcpQh\XiycnXzd4lwdiCjdDCxNEB1dyBzMECgcm0>	MYeyNVg1ODdzNh?=
CFBE41o	MVfLbY5ie2ViQYPzZZk>	MXK1JO69VQ>?		MVzEUXNQ	M2fTWWRwf25icnXneYxifGmxbjDv[kBJTEGFNzDheEAxNjJidH:gOUB2VQ>?	MXWyNVk5PDl3OB?=
CFBE41o	M3SwUWZ2dmO2aX;uJGF{e2G7	MYCxJO69VQ>?	NUfrSXdZOjRiaB?=	MV3EUXNQ	NF;LTmRT\XO2b4LheIlwdiCxZjDDSnRTKGSnbIThSlUxQCCvdYThcpQhfHKjZn\pZ4tqdmdidH:gZ4VtdCC\|dYLmZYNmKGG\|IHfsfYNw\m:{bYO=	NV\oSlJpOjF7OES5OVg>
DU145	MkOwT4lv[XOnIFHzd4F6	NHvyXJkzNjVizszN	MnjpNlQhcA>?	MWPEUXNQ	NIn0fY5KdmirYnn0bY9vKG:oIFjERWMh[XO\|ZYPz[YQh[XNidYDy[Yd2dGG2aX;uJI9nKHB{MYfh[lEheHKxdHXpckBmgHC{ZYPzbY9v	M13YdVIzOjZyMU[2
DU145	Mk\PT4lv[XOnIFHzd4F6	MmrmOUDPxE1?	Mmn5NlQhcA>?	NFLQXFdFVVOR	Mmn1TY5pcWKrdHnvckBw\iCKRFHDJIF{e2W\|c3XkJIF{KGirc4TvcoUhUDRiYXPleJlt[XSrb36=	Ml;GNlIzPjBzNk[=
DU145	M1XQN2tqdmG\|ZTDBd5NigQ>?	M3XLclUh\|ryP	MkPCNlQhcA>?	Mny3SG1UVw>?	NEnwZ2JKdmirYnn0bY9vKG:oIFjERWMh[XO\|ZYPz[YQh[XNiaHnzeI9v\SCKMzDofZBmemGlZYT5cIF1cW:w	NXH6Z2FGOjJ{NkCxOlY>
786-0	M2\Bemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3X1dlYvOiEQvF2=	NEDubJY4OiCq	Ml6wSG1UVw>?	M4f2bmdKPTB;Mz6yJO69VQ>?	NH2xSpczOjR\|NU[2PS=>
A498	M1HpUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MonKOk4zKM7:TR?=	MV[3NkBp	MWLEUXNQ	M4G1dGdKPTB;MT62JO69VQ>?	NFTMOXczOjR\|NU[2PS=>
A549/ATCC	NVnqdm5vT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3zsWFYvOiEQvF2=	NFz3bXk4OiCq	MnfSSG1UVw>?	NIj0e2lIUTVyPUGuOkDPxE1?	M37SUVIzPDN3Nk[5
ACHN	NIric\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NW\SeVRnPi5{IN88US=>	MoXPO\|IhcA>?	M1q5fWROW09?	NI\SRo5IUTVyPUGuN{DPxE1?	Mn;vNlI1OzV4Nkm=
BT549	NX\JbWI6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NE\SXJg3NjJizszN	NGXOU244OiCq	M33USWROW09?	NFL5cFJIUTVyPUGuN{DPxE1?	MnnENlI1OzV4Nkm=
EKVX	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4\hR\|YvOiEQvF2=	MWC3NkBp	MkXVSG1UVw>?	MnX1S2k2OD1zLkOg{txO	MXSyNlQ{PTZ4OR?=
HCT15	M1Hj[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVTBVVFTPi5{IN88US=>	NH3BU3k4OiCq	M2PpdWROW09?	NYHqeHUxT0l3ME2yMlUh\|ryP	NYmwWI41OjJ2M{W2Olk>
HOP92	NFq2bVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX22MlIh\|ryP	NWLZcpB[PzJiaB?=	NXnpUZJsTE2VTx?=	M3GwPGdKPTB;NDFOwG0>	MWKyNlQ{PTZ4OR?=
IGROV1	NW\xWYh{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NULXRVBzPi5{IN88US=>	NIDQO2Y4OiCq	MVTEUXNQ	MWfHTVUxRTFwMzFOwG0>	MXuyNlQ{PTZ4OR?=
LOXIMVI	MmnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnuwOk4zKM7:TR?=	NUXWPGlTPzJiaB?=	NWDsWY0zTE2VTx?=	MWrHTVUxRTFizszN	MmXCNlI1OzV4Nkm=
M14	NELzUldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIXQSXg3NjJizszN	NV34[G1RPzJiaB?=	NUjLdG1lTE2VTx?=	MmfxS2k2OD1zLkOg{txO	MlSzNlI1OzV4Nkm=
MALME-3M	NXzId\|R6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX;KS3B4Pi5{IN88US=>	NIrO[JI4OiCq	M33EemROW09?	MYnHTVUxRTBwM{Kg{txO	MWmyNlQ{PTZ4OR?=
MCF10A	NUm4e3ZLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MknEOk4zKM7:TR?=	NV7PN3FlPDhiaB?=	NEPr[WpFVVOR	MXPHTVUxRTlwNjFOwG0>	Mn\LNlI1OzV4Nkm=
MDA-MB-435	M3Ttfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIC0NJA3NjJizszN	MV63NkBp	Mkm0SG1UVw>?	NEXlRmJIUTVyPUCuOUDPxE1?	NGiwfFAzOjR\|NU[2PS=>
MDA-MB-468	M1nGZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmL5Ok4zKM7:TR?=	NFrm[oM4OiCq	NFLNdlhFVVOR	NFfadXpIUTVyPUCuOlMh\|ryP	NVGzNYhLOjJ2M{W2Olk>
MOLT4	M4LRbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2jnPFYvOiEQvF2=	NYq3T5NvPzJiaB?=	M2jy[mROW09?	M2Hmb2dKPTB;MD60JO69VQ>?	NGnMfGozOjR\|NU[2PS=>
NCI-ADR-RES	MlHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGDBNHI3NjJizszN	M1T4R\|czKGh?	M{m4e2ROW09?	MUnHTVUxRTBwMU[g{txO	M{eyTVIzPDN3Nk[5
NCI-H23	NFzWPWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVO2MlIh\|ryP	MmfZO\|IhcA>?	MWDEUXNQ	M3m1d2dKPTB;MTFOwG0>	MWiyNlQ{PTZ4OR?=
NCI-H322M	MnTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlvQOk4zKM7:TR?=	NFLKd444OiCq	NGfDSWJFVVOR	MoTwS2k2OD1yLke5JO69VQ>?	NW\2VIE{OjJ2M{W2Olk>
NCI-H460	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVi2MlIh\|ryP	NG\mem84OiCq	M4X0eGROW09?	MUHHTVUxRTBwN{mg{txO	MUSyNlQ{PTZ4OR?=
NCI-H522	MmLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M17MUFYvOiEQvF2=	MWS3NkBp	NU[yXGcyTE2VTx?=	M1nSRWdKPTB;MD61JO69VQ>?	M4PpPVIzPDN3Nk[5
OVCAR3	MkTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2HaXVYvOiEQvF2=	MX63NkBp	NWf5Z5Z6TE2VTx?=	NX;IfXo2T0l3ME2xMlMh\|ryP	MoTtNlI1OzV4Nkm=
OVCAR4	M2Hk[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVzifJUxPi5{IN88US=>	MofhO\|IhcA>?	M3XqeGROW09?	NWTLfolwT0l3ME20JO69VQ>?	NVrqZZlDOjJ2M{W2Olk>
OVCAR5	NXztcGtkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NG\oboo3NjJizszN	NGPCTGM4OiCq	NFftbIRFVVOR	M{[zTWdKPTB;MD63PUDPxE1?	M2HtVFIzPDN3Nk[5
OVCAR8	MnrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIXVVGE3NjJizszN	M3qyfFczKGh?	MoT6SG1UVw>?	MlLRS2k2OD1yLkWg{txO	NVTrOXFjOjJ2M{W2Olk>
RXF393	NFy5eJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mnv3Ok4zKM7:TR?=	NXPCU4tZPzJiaB?=	NYjjdJB{TE2VTx?=	NELnOGNIUTVyPUGuN{DPxE1?	M4PuPFIzPDN3Nk[5
SF268	NXPJfJF{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFnTd\|I3NjJizszN	MnLjO\|IhcA>?	NHGwT4pFVVOR	NETQ[YRIUTVyPUGuOkDPxE1?	MYiyNlQ{PTZ4OR?=
SF295	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4PvVFYvOiEQvF2=	NEXLN\|c4OiCq	MoLDSG1UVw>?	NFvWcI5IUTVyPUGuOkDPxE1?	M1vTSFIzPDN3Nk[5
SF539	NX7aeIRsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkPVOk4zKM7:TR?=	NGjNOIM4OiCq	NIrzfm5FVVOR	NXrDSXM5T0l3ME2yJO69VQ>?	MUeyNlQ{PTZ4OR?=
SK-MEL-2	NUTZWXBwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGqyOXk3NjJizszN	NILxfXQ4OiCq	NHvxd2JFVVOR	MXvHTVUxRTFwMzFOwG0>	MlXZNlI1OzV4Nkm=
SK-MEL-28	Mn;aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlrFOk4zKM7:TR?=	NYnjXFVVPzJiaB?=	NYnMclFLTE2VTx?=	Mkf6S2k2OD1zIN88US=>	NHrlVFgzOjR\|NU[2PS=>
SK-MEL-5	M4nhXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1;w[\|YvOiEQvF2=	NGXZdYE4OiCq	NEKyNFlFVVOR	MmPQS2k2OD1yLk[zJO69VQ>?	NWnw[\|JzOjJ2M{W2Olk>
SKOV3	NVz3SFAzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1HEXFYvOiEQvF2=	NGCyfm04OiCq	MmWzSG1UVw>?	M4Hr[GdKPTB;MTFOwG0>	MUCyNlQ{PTZ4OR?=
SN12C	MkjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUW2MlIh\|ryP	NH7jZ444OiCq	NYTp[2xMTE2VTx?=	NXLSUVJbT0l3ME2yJO69VQ>?	NETHNngzOjR\|NU[2PS=>
SNB19	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MY[2MlIh\|ryP	M1XmV\|czKGh?	NEC4VmdFVVOR	MX7HTVUxRTBwNkOg{txO	M4j4S\|IzPDN3Nk[5
SNB75	MofTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYO2MlIh\|ryP	MWO3NkBp	NH;scHdFVVOR	NYXV[HR2T0l3ME2wMlc6KM7:TR?=	NX2w[FQzOjJ2M{W2Olk>
SR	NYraVYRWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYnCS45HPi5{IN88US=>	NUG5cXh1PzJiaB?=	MXjEUXNQ	MVfHTVUxRTBwNDFOwG0>	M3rjSlIzPDN3Nk[5
T47D	NWm5So5NT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXW2MlIh\|ryP	Moi3O\|IhcA>?	M3rSTWROW09?	NYe1S3h5T0l3ME2wMlUh\|ryP	NVW5WFJbOjJ2M{W2Olk>
TK10	NFXD[2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWTDNpRjPi5{IN88US=>	NVGxNFN3PzJiaB?=	MoTUSG1UVw>?	M17pc2dKPTB;MD62N{DPxE1?	NG\seFYzOjR\|NU[2PS=>
UACC257	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2[yelYvOiEQvF2=	NHrEbJU4OiCq	MkDkSG1UVw>?	NU\TTJJkT0l3ME2wMlUh\|ryP	MonwNlI1OzV4Nkm=
UACC62	NGLiclFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUW2MlIh\|ryP	MUO3NkBp	MV3EUXNQ	NWWzfFFQT0l3ME2wMlQh\|ryP	MoCyNlI1OzV4Nkm=
UO31	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIjsdHA3NjJizszN	NX3lflA4PzJiaB?=	M4nWfGROW09?	Mn7CS2k2OD1yLkWg{txO	M17qRlIzPDN3Nk[5
Hep3B	NH\UWGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M2rVPVQ5KGh?	NVXNO4tUTE2VTx?=	MmXZS2k2OD1yLk[5JO69VQ>?	MoX0NlI1Ozl6NkO=
BE(2)-C	NGfm[4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MWO3NkBp	MXzEUXNQ	M4X3VmlEPzB;MjFOwG0>	NEPTWIQzOjl\|MkOxOi=>
Bel7402	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NVu5bHJSPzJiaB?=	Mom0SG1UVw>?	MXjHTVkxRTF5IN88US=>	NYqxWJFzOjNyNkGzO\|Y>
Bel7404	NF34R3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NXT5TJBRPzJiaB?=	MkjPSG1UVw>?	NEjZb\|VIUTlyPUG4JO69VQ>?	NYG5TpR1OjNyNkGzO\|Y>
BGC823	NHP5d4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M2Pp[VczKGh?	MUHEUXNQ	NIXIdJJIUTlyPUeuOUDPxE1?	NFjIWY0zOzB4MUO3Oi=>
MGC803	MkjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M3PLbVczKGh?	NIXPSWxFVVOR	MnjlS2k6OD1zMD64JO69VQ>?	NXHST453OjNyNkGzO\|Y>
SGC7901	NFX4NHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NHqyT4I4OiCq	MUDEUXNQ	MV;HTVkxRTlwNDFOwG0>	NFrwRVgzOzB4MUO3Oi=>
SKHEP1	NGXvU41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NHfOTYk4OiCq	MmDKSG1UVw>?	M4qxd2dKQTB;MUeg{txO	MUGyN\|A3OTN5Nh?=
SMMC7721	MkPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MYC3NkBp	MVXEUXNQ	NF;ISm5IUTlyPUKwJO69VQ>?	MnvMNlMxPjF\|N{[=
NUGC3	NIP0V\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWG4cnkyOTBizszN			Mn[5S2k:Oi57NDFOwG0>	NFizU4wzOzF4M{OzNi=>
A2780 CisR	M3ryc2tqdmG\|ZTDBd5NigQ>?		NUm0W5pOOThiaB?=		NHXvSYZKdmirYnn0bY9vKG:oIFjERWMhf2m2aDDJR\|UxKG:oIECuOFQh\|ryP	NXzhVXJ6OjN{NUK2NFM>
CAL27 sens	MmDkT4lv[XOnIFHzd4F6		MkfpNVghcA>?		Mnv5TY5pcWKrdHnvckBw\iCKRFHDJJdqfGhiSVO1NEBw\iByLkO2JO69VQ>?	MoTrNlMzPTJ4MEO=
CAL27 CisR	MVnLbY5ie2ViQYPzZZk>		NFW5TGIyQCCq		MoO5TY5pcWKrdHnvckBw\iCKRFHDJJdqfGhiSVO1NEBw\iByLk[xJO69VQ>?	NUSzRVhwOjN{NUK2NFM>
KYSE-510 CisR	MUDLbY5ie2ViQYPzZZk>		NHSwdHAyQCCq		M2K3c2lvcGmkaYTpc44hd2ZiSFTBR{B4cXSqIFnDOVAhd2ZiMD61PUDPxE1?	MU[yN\|I2OjZyMx?=
KYSE-510 sens	MX;LbY5ie2ViQYPzZZk>		MVSxPEBp		M4DiTGlvcGmkaYTpc44hd2ZiSFTBR{B4cXSqIFnDOVAhd2ZiMD63JO69VQ>?	NV;xXXpSOjN{NUK2NFM>
MDA-MB-231 sens	MXrLbY5ie2ViQYPzZZk>		MYSxPEBp		NFjQSZFKdmirYnn0bY9vKG:oIFjERWMhf2m2aDDJR\|UxKG:oIECuOlEh\|ryP	MlLDNlMzPTJ4MEO=
MDA-MB-231 CisR	MWrLbY5ie2ViQYPzZZk>		MmfuNVghcA>?		Ml\vTY5pcWKrdHnvckBw\iCKRFHDJJdqfGhiSVO1NEBw\iByLk[xJO69VQ>?	NVHwWVNVOjN{NUK2NFM>
ES2	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MmK0OFghcA>?	MYPEUXNQ	NWHu[25GUUN3ME2xNk44KM7:TR?=	NYLpcW9bOjN2OUO0OFk>
MDA-MB-231	M{P3[WtqdmG\|ZTDBd5NigQ>?	M3W0NlExKM7:TR?=	M{nxNFMxKG2rbh?=	NEGz[WFFVVOR	MoSzTY5pcWKrdHnvckBw\iCKRFHDNoE>	Mn\VNlM1QTN2NEm=
MDA-MB-231	MX;LbY5ie2ViQYPzZZk>	NHn5ZYEyKM7:TR?=	NUTYN4I6OjRiaB?=	Mn3GSG1UVw>?	NX\VbJhCUW6qaXLpeIlwdiCxZjDISGFEPiCjc4Pld5Nm\CCjczDhZ4V1gWyjdHnvckBt\X[nbIOgc4YhfHWkdXzpci=>	NUi4cHJUOjN2OUO0OFk>
HS68	NVfFN5NpS3m2b4TvfIlkKEG\|c3H5	M4nl[FExKM7:TR?=	MVi3NkBp	NE[yUIFFVVOR	MYDJR\|UxRTRwNjFOwG0>	NXq2NFZLOjN3N{C1OFI>
MEF	NXPZV5dWS3m2b4TvfIlkKEG\|c3H5	NWXP[GlHOTBizszN	NFz3b244OiCq	MmDmSG1UVw>?	MX\JR\|UxRTRwNDFOwG0>	MWeyN\|U4ODV2Mh?=
BGC823	NYP3PYlDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			Mmr6SG1UVw>?	M3fyVmdKPTB;Mz6wPUDPxE1?	MVmyN\|YxOTdyNh?=
High5	M3TpOGtqdmG\|ZTDBd5NigQ>?		M3jWSFI1KGh?		M{jLUmlvcGmkaYTpc44hd2ZiaIXtZY4hemWlb33ibY5idnRiSFTBR\|Yhf2m2aDDJR\|UxKG:oIECuNFkh\|ryP	M2LYdFI{PjB{NUKz
High5	NXXqXmFsU2mwYYPlJGF{e2G7		MX6yOEBp		M4HhPGlvcGmkaYTpc44hd2ZiaIXtZY4hemWlb33ibY5idnRiSFTBR\|Ehf2m2aDDJR\|UxKG:oIECuNVIh\|ryP	Ml7ZNlM3ODJ3MkO=
High5	Ml71T4lv[XOnIFHzd4F6		NFXQXpczPCCq		MV7Jcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KEiGQVOzJJdqfGhiSVO1NEBw\iByLkG3JO69VQ>?	Mo\iNlM3ODJ3MkO=
A549	M{C3OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M4jGcmROW09?	MY\JR\|UxRTFwMEe5JO69VQ>?	NYfDXpNCOjN4NESyNVA>
HCT116	NYPJRmJzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MnWwSG1UVw>?	NH;idlZKSzVyPUCuO\|U4KM7:TR?=	NYPucXZFOjN4NESyNVA>
K562	M{XBXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M4TtNWROW09?	NVLaOJFnUUN3ME2wMlY1PSEQvF2=	NEjyO2ozOzZ2NEKxNC=>
GBC-SD	NEXhVZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoWxOUDPxE1?	NUjoTYw3PzJiaB?=	M2TnbGROW09?	MWXJR\|UxRTF2Lkig{txO	MWCyN\|cxPzJ4MB?=
HGC27	MofZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYO1JO69VQ>?	M33RTlczKGh?	MV7EUXNQ	NF[zRpVKSzVyPUWuOEDPxE1?	Mkm1NlM4ODd{NkC=
HL60	NGnMfFFMcW6jc3WgRZN{[Xl?	M2DJVlUh\|ryP	MnToNlQhcA>?	M1HkTWROW09?	MWnJcohq[mm2aX;uJI9nKEiGQVO=	MUSyN\|cxPzJ4MB?=
Vero	M2H2Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NEjNd5A4OiCq	MlX1SG1UVw>?	MXHJR\|UxRTBwOTFOwG0>	M{XXd\|I{Pzh4NEWy
NCI60	MXfDfZRwfG:6aXOgRZN{[Xl?		NYizfoduPDhiaB?=	NE\5dnVFVVOR	NFuxcXRIUT1yLkWzJO69VQ>?	NVPqW4FGOjRyMUWzNlc>
SW620	M3\semN6fG:2b4jpZ{BCe3OjeR?=		M3XoblQ5KGh?	NF;hSFZFVVOR	M{LKdGdKRTBwNUSg{txO	NIXvSHgzPDBzNUOyOy=>
U251	NGn2N5lEgXSxdH;4bYMhSXO\|YYm=		MkfoOFghcA>?	M{HnOGROW09?	M2[wT2dKRTFwNUOg{txO	MonWNlQxOTV\|Mke=
KM12	MYjDfZRwfG:6aXOgRZN{[Xl?		NHG1XFY1QCCq	M324TmROW09?	NX32[G11T0l;MT64PEDPxE1?	NHXYcJQzPDBzNUOyOy=>
Hs578T	MoG2R5l1d3SxeHnjJGF{e2G7		NXzp[VlrPDhiaB?=	NHvhcIVFVVOR	MXfHTV01Njh\|IN88US=>	NUnQcXhQOjRyMUWzNlc>
MDA-MB-231	NVXrW5Y3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NUG3PWlmPDhiaB?=		M1zvdGlEPTB;MD6xOkDPxE1?	MUOyOFA6PTBzNh?=
MCF7	MmOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NXPzWmFsPDhiaB?=		Ml;1S2k:OC52NTFOwG0>	MXeyOFEyQTV3NR?=
MDA-MB-435	NEPvNGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NHnxVFY1QCCq		MXPHTV0xNjh6IN88US=>	MWOyOFEyQTV3NR?=
AsPC1	NWrPTpZET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVvvdXk1OzBizszN	MYq0PEBp	NVXUZZZ6TE2VTx?=	M2fwSGlEPTB;Mz62OkDPxE1?	M2HKfFI1OTh3M{e4
Jurkat E6.1	NV7uPYhsU2mwYYPlJGF{e2G7		NUf2fVF4OiCq	M2T0XGROW09?	MlPZTY5pcWKrdHnvckBw\iCKRFHDOEB4cXSqIFnDOVAhd2ZiMD6wOEDPxE1?	M1SyfFI1OjZzOE[y
KG1	NH:y[XhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MmK5OFghcA>?		MYfJR\|UxRTFwMUWg{txO	M3HubFI1PTJ3MECz
HEL	Mm[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NXjXOmlUPDhiaB?=	Ml3TSG1UVw>?	M1f6cWlEPTB;MD60PUDPxE1?	NHS4TYszPDZ7NEC1OS=>
HSC3	MknyR5l1d3SxeHnjJGF{e2G7		NV;pSYlNOTJiaB?=	MW\EUXNQ	M{frXmlEPTB;MD63NUDPxE1?	M4LFWlI1PzZ4NU[w
HT-29	MVnDfZRwfG:6aXOgRZN{[Xl?		M1jtPFEzKGh?	M1ny[mROW09?	MkDwTWM2OD1yLkeyJO69VQ>?	NWPEUpI3OjR5Nk[1OlA>
KB	M4DrcWN6fG:2b4jpZ{BCe3OjeR?=		MWKxNkBp	NV3oNW1WTE2VTx?=	MYfJR\|UxRTBwN{Wg{txO	M3\RUFI1PzZ4NU[w
H460	MlTSR5l1d3SxeHnjJGF{e2G7		Mk\6NVIhcA>?	MmrUSG1UVw>?	NGLufIVKSzVyPUCuPFIh\|ryP	M1vpcFI1PzZ4NU[w
MONE1	NILOT5JEgXSxdH;4bYMhSXO\|YYm=		MX6xNkBp	NXP5NVBTTE2VTx?=	M4C0SmlEPTB;MT6xPEDPxE1?	M2nNelI1PzZ4NU[w
MKN45	NW[zR5RlS3m2b4TvfIlkKEG\|c3H5		MVuxNkBp	NYjGXoVsTE2VTx?=	M2\LXmlEPTB;MT6yOUDPxE1?	MYCyOFc3PjV4MB?=
TSGH	M4n0XmN6fG:2b4jpZ{BCe3OjeR?=		NFq1cXMyOiCq	NVjQZXkyTE2VTx?=	MVrJR\|UxRTJwMEmg{txO	NEH0fFAzPDd4NkW2NC=>
HL60	M2i1Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M2Ta[FczKGh?	MnyySG1UVw>?	MmfMS2k2OD1yLkmzJO69VQ>?	MknSNlQ6ODB3MEC=
HEK293	NFjaS3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NH[1TJY4OiCq	NEPZfGdFVVOR	MlvsS2k2OD1zMzFOwG0>	M4TOR\|I1QTByNUCw
Jurkat	Mm\oR5l1d3SxeHnjJGF{e2G7	NELQUFgyODBizszN	NFv5UGQ4OiCq		NFj0O29IUTVyPUCuPUDPxE1?	M1G0TlI1QTByN{Sz
GM15850	NVTGe3o3U2mwYYPlJGF{e2G7	MXyyMlUh\|ryP	NFfsdIk6PiCq	M{LUWWROW09?	NWm5eZJm\G:nczDuc5QhcW6qaXLpeEBJTEGFIHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKGirc4TvcoUhUDNibInzbY5mKDF2IHHj[ZR6dGG2aX;uJI9nKE[[TjDn[Y5m	MWSxOlkzOTN4Nx?=
GM15850	NHfiO\|VMcW6jc3WgRZN{[Xl?	M{HCN\|IvPSEQvF2=	NEHodIU6PiCq	M1e5VGROW09?	MmrC[I9meyCwb4SgbY5pcWKrdDDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFQhdHm\|aX7lJFUh[WOndInsZZRqd25ib3[gSnhPKGenbnW=	NVnFOpkyOTZ7MkGzOlc>
GM15850	MXTLbY5ie2ViQYPzZZk>	NXmzVmpIOi53IN88US=>	MlvjPVYhcA>?	NHXIfmJFVVOR	M3XJW4Rw\XNibn;0JIlvcGmkaYSgTGRCSyCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDpckBpcXO2b37lJGg1KGy7c3nu[UAyOiCjY3X0fYxifGmxbjDv[kBHYE5iZ3Xu[S=>	MoTpNVY6OjF\|Nke=
GM15850	M{H5ZWtqdmG\|ZTDBd5NigQ>?	NF3wXYUzNjVizszN	MlrXPVYhcA>?	NX3JW5B[TE2VTx?=	MXvkc4V{KG6xdDDpcohq[mm2IFjERWMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDIN{BtgXOrbnWgPUBi[2W2eXzheIlwdiCxZjDGXG4h\2WwZR?=	NV\2U4dMOTZ7MkGzOlc>
GM15850	M2i4UGtqdmG\|ZTDBd5NigQ>?	NEHXZ4IzNjVizszN	MXO5OkBp	Mkf4SG1UVw>?	M2DaR4Rw\XNibn;0JIlvcGmkaYSgTGRCSyCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDpckBpcXO2b37lJGg1KGy7c3nu[UA5KGGlZYT5cIF1cW:wIH;mJGZZViCpZX7l	M2L4dVE3QTJzM{[3
GM15850	MnnwT4lv[XOnIFHzd4F6	MmrONk42KM7:TR?=	NH71SHU6PiCq	MV7EUXNQ	NG\0eJFld2W\|IH7veEBqdmirYnn0JGhFSUNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4hcGm\|dH;u[UBJPCCueYPpcoUhOTZiYXPleJlt[XSrb36gc4YhTliQIHflcoU>	NX;xVJBVOTZ7MkGzOlc>
GM15850	MWPGeY5kfGmxbjDBd5NigQ>?	NGfZSmE2KM7:TR?=	MkewNVIhcA>?	M4f5Z2ROW09?	Mm\XbIF{KG6xIHXm[oVkfCCxbjDGXG4hdVKQQTDlfJBz\XO\|aX;u	MmrSNVY6OjF\|Nke=
U937	M3yycWtqdmG\|ZTDBd5NigQ>?	M1zVdlUh\|ryP	NF20S5ozPCCq	NX3OS3B1TE2VTx?=	NIr5SnNp[XNibn:g[YZn\WO2IH;uJIFteGijIIT1ZpVtcW5iYXPleJlt[XSrb36=	MV2xO\|Q1Pzd3MB?=
U937	NELkTmFMcW6jc3WgRZN{[Xl?	NGnLfVAyKM7:TR?=	M3rXUlI1KGh?	NIfpTYZFVVOR	MVLoZZMhdm9iZX\m[YN1KG:wIHHsdIhiKHS3YoXsbY4h[WOndInsZZRqd25?	M331O\|E4PDR5N{Ww
PANC1	NWPWU2s6TnWwY4Tpc44hSXO\|YYm=	NUXkfWNHOSEQvF2=	MVmyOEBp		M4HlToRw\XNibn;0JIlv[3KnYYPlJIlvKHB{N3vpdFEh\2WwZTDlfJBz\XO\|aX;u	NEL1SHAyPzV6OEe0OC=>
PANC1	M1XFPGZ2dmO2aX;uJGF{e2G7	NFXidJQyKM7:TR?=	NWLsT5M6PDhiIHi=		M2TWeoRw\XNibn;0JIlv[3KnYYPlJIlvKHB{N3vpdFEh\2WwZTDlfJBz\XO\|aX;u	NY\2N2MzOTd3OEi3OFQ>
Caco-2	NWrsW2dzTnWwY4Tpc44hSXO\|YYm=	NXvFdVlzPSEQvF2=	MXuyOEBp	NX64PWNvTE2VTx?=	MoTj[I9meyCwb4SgbY5lfWOnIGCyNXdCTjFiZ3Xu[UBmgHC{ZYPzbY9v	MYKyNFE1Ozh2MB?=
SCC4	M2PvdGZ2dmO2aX;uJGF{e2G7	NE\oZ28yKM7:TR?=	NUTRVopjOTBibXnu	NY\vTWFnTE2VTx?=	NGniZVhp[XNibn:gZYdwdmm\|dDDhZ5Rqfmm2eTDheEBXTFJiYYPz[ZN{\WRiYYOgbY5lfWO2aX;uJI9nKEO\UEK0JIdmdmViZYjwdoV{e2mxbh?=	M4jZdVIxPDV{MkK1
A549	NVnCUohbTnWwY4Tpc44hSXO\|YYm=	Mn7OOUDPxE1?	NGjtSYs{KGh?	M1\He2ROW09?	MV7kc4V{KG6xdDDpcoR2[2ViYYX0c5Bp[We7IHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKEyFM1nJ	NV7HdXVDOjB6NUWyNFg>
HCT116	NVr2eIM4U2mwYYPlJGF{e2G7	NEjYSIIxNjNizszN	NXToe4FmOzBiaB?=	MojpSG1UVw>?	MnLz[I9meyCwb4SgbY5pcWKrdDDISGFEOSCjc4Pld5Nm\CCjczDpcoR2[3Srb36gc4YhcGm\|dH;u[UBJO0t7IHHj[ZR6dGG2aX;u	MVKyNVA5ODZ2Nx?=
HepG2	MkXYSpVv[3Srb36gRZN{[Xl?	Mk\WNVAh\|ryP	M1vGWFI1KGh?	MWjEUXNQ	Mn;W[I9meyCwb4SgbY5lfWOnIHHwc5B1d3OrczDhd5Nme3OnZDDhd{BpgXCncnHj[ZR6dGG2aX;uJI9nKHB3Mx?=	NHTmT\|kzOTV2OEW4Ni=>
GM11272	MUDGeY5kfGmxbjDBd5NigQ>?	MVWwMlEh\|ryP	MkPtO\|IhcA>?	NHvHeGJFVVOR	NUnkfFlm\G:nczDuc5QhemWjY4TpeoF1\SCPZVPwNkBufXSjboSg[ZhxemW\|c3nvci=>	NHv1WpUzOTh2MEexOi=>
MDA-MB-231	NIDlUJNMcW6jc3WgRZN{[Xl?	MnPUNVAh\|ryP	M{PKU\|UhdWmw	M1G1bmROW09?	MoW1[I9meyCwb4SgbY5pcWKrdDDISGFEOmF?	NX7meZJ1OjN2OUO0OFk>
MDA-MB-231	NYLHc2dxU2mwYYPlJGF{e2G7	NYP0eHhqOSEQvF2=	NGDzZWkzPCCq	NHftPWpFVVOR	M1f6XYRw\XNibn;0JIlvcGmkaYSgTGRCSzZiYYPz[ZN{\WRiYYOgZYNmfHmuYYTpc44hdGW4ZXzzJI9nKHS3YoXsbY4>	NVvTVXhOOjN2OUO0OFk>
K562	M4r3cGtqdmG\|ZTDBd5NigQ>?				NGfHcJlld2W\|IH7veEBqdmirYnn0JGhFSUN?	NFTiRW8zOzV7MUGxNS=>
Jurkat	MlvBR5l1d3SxeHnjJGF{e2G7	MlnwNlAh\|ryP	NWHUe5M{PzJiaB?=	Ml;5SG1UVw>?	Mlfuco8h[3m2b4TvfIlkcXS7IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;u	Ml3KNlQ{ODR\|NEi=
HCT116	NYHjc2lkSXCxcITvd4l{KEG\|c3H5	NYHoTmZOOyEQvF2=	NWPrXndTOjRiaB?=	MV\EUXNQ	NGfwOXRld2W\|IH7veEBqdmS3Y3WgZZBweHSxc3nzJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIIC1N{Bxem:2ZXnuJIxmfmWu	NF;Ke48zPDd4NkW2NC=>
KASUMI-1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Moq4TWM2OD17OT6xO{BvVQ>?	NYTa[GFZW0GQR1XS
KARPAS-45	M2LUT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXPJR\|UxRTF5Mz64PUBvVQ>?	MnjHV2FPT0WU
BHT-101	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXXJR\|UxRTJ2ND6xPEBvVQ>?	MVfTRW5ITVJ?
H9	NYfK[5hVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXPsUG1tUUN3ME2yOVUvODRibl2=	NFjwcmVUSU6JRWK=
PA-1	MmHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4HoO2lEPTB;Mki2MlI3KG6P	NHjvXHZUSU6JRWK=
NEC8	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWrJR\|UxRTJ6OT6zPEBvVQ>?	NEPEcVZUSU6JRWK=
MHH-PREB-1	NXzQW2F{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mm\pTWM2OD1{OUSuOVMhdk1?	MUXTRW5ITVJ?
NB7	MkK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWfJR\|UxRTN2NT63OEBvVQ>?	NFGxSWRUSU6JRWK=
A3-KAW	M{XQfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUPvNnRvUUN3ME20NFAvPTlibl2=	MkG2V2FPT0WU
NB69	MnLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYrnTXhwUUN3ME20NVEvPzFibl2=	M3[wSnNCVkeHUh?=
EoL-1-cell	NVLzcoxDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGHhZVBKSzVyPUS1OFI2KG6P	MoLEV2FPT0WU
CHP-212	NWnzVZNlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkXsTWM2OD12NUeuOVMhdk1?	NGrWd4ZUSU6JRWK=
C2BBe1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYr1NYw4UUN3ME20O\|IvOTlibl2=	M1\p[3NCVkeHUh?=
697	MlnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MonUTWM2OD12N{OuOFEhdk1?	NWDvTJR2W0GQR1XS
BCPAP	NW\mfIFVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmHUTWM2OD13MEGuOFIhdk1?	NGHFO25USU6JRWK=
L-363	NHnvT\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mk\iTWM2OD13MEOuNUBvVQ>?	MY\TRW5ITVJ?
ES8	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWHweIpSUUN3ME21NlMvPTNibl2=	MkLQV2FPT0WU
BE-13	M3Lxfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYDEO\|Q6UUN3ME21NlYvQTZibl2=	MnO1V2FPT0WU
CTB-1	NFruVJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYnLOHZCUUN3ME21N\|cvQTJibl2=	MVHTRW5ITVJ?
HD-MY-Z	MmH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnnJTWM2OD13M{iuNVMhdk1?	NXLT[mZ6W0GQR1XS
NKM-1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NITYXolKSzVyPUW0OE4zPyCwTR?=	M4eweXNCVkeHUh?=
NCI-H720	NF3TXFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnnlTWM2OD13NkCuNVghdk1?	MomwV2FPT0WU
KY821	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWHJR\|UxRTV4Mz6yOUBvVQ>?	MVzTRW5ITVJ?
OVCAR-5	MmDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUPJR\|UxRTV5Nj6xNUBvVQ>?	NF;tVHJUSU6JRWK=
CTV-1	Ml\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXnJR\|UxRTV6MT61OkBvVQ>?	M1L4SnNCVkeHUh?=
P12-ICHIKAWA	MlnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGnGVWtKSzVyPUW5Ok42OSCwTR?=	M3u2bHNCVkeHUh?=
DB	NYL0[5hvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVnreZdoUUN3ME21PVgvPTdibl2=	MmLGV2FPT0WU
CHL-1	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHjtV\|dKSzVyPU[0Nk4xQCCwTR?=	NGnD[YtUSU6JRWK=
A4-Fuk	NYrpbXJIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml7QTWM2OD14NESuPVEhdk1?	NH31[2NUSU6JRWK=
MV-4-11	NGXEXmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWXJR\|UxRTZ3OT6xJI5O	NUi1N4VDW0GQR1XS
RPMI-8226	NG\6Z5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXfJR\|UxRTZ5OD6xPEBvVQ>?	NFTLeJJUSU6JRWK=
NB14	NYjKWmZiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkHuTWM2OD14OU[uPVUhdk1?	M{P4R3NCVkeHUh?=
DOHH-2	NGHET2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXzQSZR3UUN3ME23NFYvPjhibl2=	NHXZbY1USU6JRWK=
D-423MG	NWTuV\|Y5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mni5TWM2OD15ME[uPFkhdk1?	M2Li[XNCVkeHUh?=
D-283MED	M17SbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWHYSIRvUUN3ME23NVQvOTRibl2=	Mmr4V2FPT0WU
ES1	M3Gydmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M33RT2lEPTB;N{K0MlQhdk1?	NIjJOIlUSU6JRWK=
GOTO	M37sTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHnUN2hKSzVyPUeyPU4yOiCwTR?=	MVvTRW5ITVJ?
NCI-H209	M33LV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH6xVXFKSzVyPUeyPU46KG6P	NW\5T4N5W0GQR1XS
MOLT-13	MmfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYjyXZF6UUN3ME23N\|gvQThibl2=	NEDsU49USU6JRWK=
ATN-1	MoDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFm5UplKSzVyPUe0NE4zQCCwTR?=	MoSzV2FPT0WU
DU-4475	NVns[oZET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXvJR\|UxRTd3MT65NUBvVQ>?	MlL4V2FPT0WU
NB10	MlfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NG\MVppKSzVyPUe1NU46OiCwTR?=	NVLwPWJLW0GQR1XS
KG-1	NWTWXJpOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml62TWM2OD15N{WuOFUhdk1?	NHXwOlVUSU6JRWK=
MOLT-4	M3i0ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXTJR\|UxRTd6Nz60OkBvVQ>?	M{XOZ3NCVkeHUh?=
TE-1	M13oeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmPqTWM2OD15OUGuNUBvVQ>?	M1fNenNCVkeHUh?=
SBC-1	NFy1UoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M17xWWlEPTB;N{mzMlg1KG6P	MUPTRW5ITVJ?
HEL	NUTMbGJxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYTCeFE3UUN3ME24NFYvODhibl2=	NXXpd3NtW0GQR1XS
SK-MEL-2	NF;o[oRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmXLTWM2OD16MEmuOFQhdk1?	M{fwT3NCVkeHUh?=
KU812	M{nUdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2j5ZWlEPTB;OEGzMlEhdk1?	MWjTRW5ITVJ?
RPMI-8866	M3vJVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MonyTWM2OD16MUOuOlchdk1?	NHTZZlNUSU6JRWK=
ALL-PO	NWrZNG5lT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHXsOm5KSzVyPUixOE43PiCwTR?=	MVXTRW5ITVJ?
LU-139	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWTqUW1vUUN3ME24NlIvQDZibl2=	MYXTRW5ITVJ?
RS4-11	M4eyVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnztTWM2OD16M{KuOFUhdk1?	NXnFc2tvW0GQR1XS
EW-18	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVfJR\|UxRTh\|Mj65OkBvVQ>?	MWXTRW5ITVJ?
P30-OHK	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{HKXmlEPTB;OEO1Mlchdk1?	NGTjPVdUSU6JRWK=
D-566MG	NGOyNnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV3JR\|UxRTh\|OD62NkBvVQ>?	M1fFcnNCVkeHUh?=
HSC-4	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH\w[YRKSzVyPUi0Ok42OSCwTR?=	NECzZXBUSU6JRWK=
QIMR-WIL	MoTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUHJR\|UxRTh4Mj6wN{BvVQ>?	NVfxPJVIW0GQR1XS
SW954	MkTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmnvTWM2OD16NkOuNVYhdk1?	NI\tVYpUSU6JRWK=
HGC-27	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEe1[HJKSzVyPUi3Nk4{PCCwTR?=	M{jlbXNCVkeHUh?=
HH	NWnTXYFJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEfzU49KSzVyPUi5OE4yOiCwTR?=	MkLRV2FPT0WU
KE-37	NYDsOnVrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NILEW2FKSzVyPUi5OE43OiCwTR?=	M1f4[3NCVkeHUh?=
SK-N-DZ	MlrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVnJR\|UxRTlyMD60N{BvVQ>?	M1WwRnNCVkeHUh?=
J-RT3-T3-5	M{PLfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MU\JR\|UxRTlzMD60PUBvVQ>?	M{fuZ3NCVkeHUh?=
A427	MnXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYPZ[G9xUUN3ME25NlAvQDRibl2=	MVXTRW5ITVJ?
ECC10	M4nrVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVryNI5bUUN3ME25OFUvQDdibl2=	NETCdY9USU6JRWK=
EW-1	MnzyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4nr[2lEPTB;OUS3MlI3KG6P	MkLoV2FPT0WU
MIA-PaCa-2	NEXNUopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHrZV3VKSzVyPUm0PU4yOiCwTR?=	NGG3U4NUSU6JRWK=
HCC2218	NYDVdHgxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MonKTWM2OD17NUiuOFghdk1?	NFPH[JlUSU6JRWK=
HAL-01	NH3V[45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoLvTWM2OD17NkiuNFQhdk1?	MnnJV2FPT0WU
RD	NIrXcFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3TDPGlEPTB;OUe0MlQ2KG6P	NUKzVXV7W0GQR1XS
SK-N-AS	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4fwS2lEPTB;OUi4MlEhdk1?	NFPDN5VUSU6JRWK=
ML-2	NYHyWpZLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGW0cYtKSzVyPUGuNFA1ODdizszN	MlLyV2FPT0WU
MEL-HO	MmHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWLJR\|UxRTFwMEC1PFIh\|ryP	NU\mcVJCW0GQR1XS
MS-1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlT3TWM2OD1zLkCwOlE4KM7:TR?=	NFfKeFNUSU6JRWK=
NCI-SNU-1	M{DBSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlnPTWM2OD1zLkCyN\|MyKM7:TR?=	MVPTRW5ITVJ?
8505C	NEi2TGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUHJR\|UxRTFwMEKzN\|Eh\|ryP	NX3UU41lW0GQR1XS
MN-60	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV\2OolKUUN3ME2xMlAzPjhizszN	NHfGS45USU6JRWK=
SAS	NVPseod1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1rhXGlEPTB;MT6wOFA5OSEQvF2=	NHSyTFZUSU6JRWK=
EFM-19	M2DyVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUnJR\|UxRTFwMES4O\|kh\|ryP	MVfTRW5ITVJ?
Ca9-22	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoDFTWM2OD1zLkC1NVA4KM7:TR?=	NVjCNYRwW0GQR1XS
NBsusSR	M3rIT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXXSWmxWUUN3ME2xMlA2OTZ4IN88US=>	MYnTRW5ITVJ?
NB13	NWjONY1xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYP1eWlMUUN3ME2xMlA2PTBzIN88US=>	Ml;iV2FPT0WU
SF295	MoDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml7BTWM2OD1zLkC2OlI1KM7:TR?=	NFvodGNUSU6JRWK=
U-2-OS	NELubIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX3DfFZtUUN3ME2xMlA4QTFzIN88US=>	MV3TRW5ITVJ?
NCI-H526	NGf3NYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1XK[2lEPTB;MT6wPFI6OSEQvF2=	NWm3[lhPW0GQR1XS
KMOE-2	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWnJR\|UxRTFwMEm0NlIh\|ryP	MkK5V2FPT0WU
RCM-1	MmDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{n1emlEPTB;MT6xNlExOiEQvF2=	M371WnNCVkeHUh?=
MC116	NWn0cZR4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV3iSoIzUUN3ME2xMlE{PjJzIN88US=>	NFjJcGtUSU6JRWK=
NCI-H1092	NXLPUnJHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFnBXIhKSzVyPUGuNVU1ODZizszN	NUTrbpcyW0GQR1XS
EW-3	MnTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIXifnRKSzVyPUGuNVczOTJizszN	M2X0NHNCVkeHUh?=
HCT-116	MlLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHz4co9KSzVyPUGuNVc4PSEQvF2=	M2[zO3NCVkeHUh?=
MC-IXC	MkjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mo\wTWM2OD1zLkG3PFgyKM7:TR?=	M1O3WXNCVkeHUh?=
LB1047-RCC	M3H6dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkjWTWM2OD1zLkG4N\|EzKM7:TR?=	MmrNV2FPT0WU
VM-CUB-1	NETCXZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVHkeHFYUUN3ME2xMlE6OTB6IN88US=>	NYLsO4xKW0GQR1XS
NB5	M2L1[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFTHUHRKSzVyPUGuNVk5PTZizszN	NX7xdphSW0GQR1XS
SKG-IIIa	NGSwO2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXXJR\|UxRTFwMkO0OlQh\|ryP	Mk\OV2FPT0WU
HO-1-N-1	NVfjNWg{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1rT[mlEPTB;MT6yN\|g{PSEQvF2=	MX3TRW5ITVJ?
EFO-27	NGrWb2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4r5bGlEPTB;MT6yOVA1OyEQvF2=	NIrjWoZUSU6JRWK=
MHH-NB-11	M3fRfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkTMTWM2OD1zLkK4N\|I6KM7:TR?=	M4j0fXNCVkeHUh?=
SW620	MnfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGXDN4FKSzVyPUGuNlkxOThizszN	NHnXdJZUSU6JRWK=
MOLT-16	Mn7xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWTZbppNUUN3ME2xMlI6Pzl5IN88US=>	NH:5ZmZUSU6JRWK=
NTERA-S-cl-D1	NH;MemRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn3ITWM2OD1zLkOxO\|YyKM7:TR?=	M4XO[3NCVkeHUh?=
VA-ES-BJ	MofPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2Pq[2lEPTB;MT6zNlQ4PyEQvF2=	MWXTRW5ITVJ?
HCC1419	MknCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2rUPGlEPTB;MT6zOFAzPyEQvF2=	NFfuOWlUSU6JRWK=
NCI-H69	Mn\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mlz0TWM2OD1zLkO0NVEzKM7:TR?=	M1zN[XNCVkeHUh?=
DEL	NYnw[ohYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUTObllWUUN3ME2xMlM2OTZ{IN88US=>	NFHOOpBUSU6JRWK=
LXF-289	NUHmb2w5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXfJR\|UxRTFwM{WyOEDPxE1?	NU\MWVNOW0GQR1XS
EW-11	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MorPTWM2OD1zLkO2NFI3KM7:TR?=	MXjTRW5ITVJ?
KP-4	M1Xm[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1TmNmlEPTB;MT6zO\|A5PSEQvF2=	NXfyOoFLW0GQR1XS
NOS-1	NEnSd2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3q4VGlEPTB;MT60NVE6PCEQvF2=	MYPTRW5ITVJ?
SK-NEP-1	MmHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWXJR\|UxRTFwNEG2PVMh\|ryP	M1ezcXNCVkeHUh?=
LAMA-84	NV7teYNjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVfJR\|UxRTFwNEO5OFUh\|ryP	MoDjV2FPT0WU
ES5	MnTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmLxTWM2OD1zLkS0N{DPxE1?	MX7TRW5ITVJ?
HuO9	NXvZTFc3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFK2eoZKSzVyPUGuOFU{PjJizszN	NWTiblZGW0GQR1XS
COLO-684	MmiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXXJR\|UxRTFwNE[xNVgh\|ryP	NInLb\|RUSU6JRWK=
EW-24	NWX3bWJsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVK2fWx7UUN3ME2xMlQ3PTNzIN88US=>	NIPjSJpUSU6JRWK=
BV-173	NGO1fZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NE\6V2tKSzVyPUGuOFczQTFizszN	MonxV2FPT0WU
NCI-H1770	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYPJR\|UxRTFwNEi1N\|Yh\|ryP	Mlz2V2FPT0WU
HuP-T4	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUnXcZQ1UUN3ME2xMlQ6OyEQvF2=	MUDTRW5ITVJ?
TYK-nu	NEnoUZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVPJR\|UxRTFwNEm4OVEh\|ryP	MmjvV2FPT0WU
YH-13	Mo[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2GzWmlEPTB;MT60PVg6PCEQvF2=	NUHuUpBEW0GQR1XS
H4	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1vPOWlEPTB;MT61NFkyOiEQvF2=	MkP0V2FPT0WU
OVCAR-8	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWHQTnBtUUN3ME2xMlU1PDd5IN88US=>	M1HuTHNCVkeHUh?=
NCI-H23	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFHtUotKSzVyPUGuOVQ3PDVizszN	MlzxV2FPT0WU
ES7	Mk\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH3qSnhKSzVyPUGuOVQ4PzNizszN	NF\TbWdUSU6JRWK=
COR-L88	M{H2fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M13VfGlEPTB;MT61OlQzPCEQvF2=	MnK3V2FPT0WU
TI-73	NXO2cXc3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUPHcmRyUUN3ME2xMlU6ODZizszN	M4\zNXNCVkeHUh?=
RT-112	NY\2emhkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MljqTWM2OD1zLkW5Nlg1KM7:TR?=	MX\TRW5ITVJ?
HuO-3N1	MmK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3XtfmlEPTB;MT61PVM5PSEQvF2=	M4jlNHNCVkeHUh?=
HC-1	M2HpeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYDJR\|UxRTFwNUm4OlYh\|ryP	MoLUV2FPT0WU
HT55	NWrVUnhCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnLSTWM2OD1zLk[1NVMyKM7:TR?=	NVjIPZJYW0GQR1XS
IA-LM	MnrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlvyTWM2OD1zLk[5Nlc5KM7:TR?=	NFjy[Y5USU6JRWK=
EM-2	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWHJR\|UxRTFwN{CwNVQh\|ryP	NHvUNldUSU6JRWK=
MHH-ES-1	M{nRR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF2xeYJKSzVyPUGuO\|A1OzVizszN	NWrNW\|RVW0GQR1XS
CAL-27	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M33WOmlEPTB;MT63NFYzOSEQvF2=	NHLGOFZUSU6JRWK=
COLO-800	NF3ufZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEnNTFlKSzVyPUGuO\|EyPzlizszN	MlLhV2FPT0WU
HCE-T	NE\ZXIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2Dh[mlEPTB;MT63NVUh\|ryP	MX;TRW5ITVJ?
CAMA-1	M1q0b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUm5RnNrUUN3ME2xMlcyQTdzIN88US=>	MojwV2FPT0WU
LOXIMVI	MmfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHPHU41KSzVyPUGuO\|IyOSEQvF2=	NWezWVVDW0GQR1XS
NH-12	NWHk[ohlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NU\qOmxtUUN3ME2xMlczPjlzIN88US=>	NVLBRYd5W0GQR1XS
TCCSUP	Mnv6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnfkTWM2OD1zLkeyPFI6KM7:TR?=	M1P6eHNCVkeHUh?=
MDA-MB-361	M3nuRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFzzb5RKSzVyPUGuO\|MyPTdizszN	M175THNCVkeHUh?=
EW-16	NFzJbmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmjQTWM2OD1zLke0NVA4KM7:TR?=	NVPIOWFUW0GQR1XS
SNU-423	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1r0bmlEPTB;MT63OVgzPyEQvF2=	MYTTRW5ITVJ?
Daoy	NHfP[3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGXMb3pKSzVyPUGuO\|Y{OTlizszN	M2nwbnNCVkeHUh?=
ES4	M3POT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlvGTWM2OD1zLke4O\|QyKM7:TR?=	MXTTRW5ITVJ?
PFSK-1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGi4VWJKSzVyPUGuPFA{PyEQvF2=	NVfrfFd{W0GQR1XS
ES3	NVzYb3hPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGHFS\|BKSzVyPUGuPFI3QDFizszN	M2jhR3NCVkeHUh?=
ONS-76	Ml36S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYTnS5BtUUN3ME2xMlgzQDl5IN88US=>	NVfpW2lMW0GQR1XS
JVM-3	M322UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUfJR\|UxRTFwOEW0OVEh\|ryP	NYKxelF2W0GQR1XS
OS-RC-2	M4rpR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV3JR\|UxRTFwOEexOVEh\|ryP	NGi3cVVUSU6JRWK=
COLO-320-HSR	Mn3xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mny1TWM2OD1zLki4NVk4KM7:TR?=	M4q0fHNCVkeHUh?=
HN	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWjJR\|UxRTFwOEi3NlUh\|ryP	MmHnV2FPT0WU
HT	MlLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX\BfXZFUUN3ME2xMlg5QTR5IN88US=>	NGXVe4VUSU6JRWK=
LoVo	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M13PR2lEPTB;MT64PVgyKM7:TR?=	MUHTRW5ITVJ?
CGTH-W-1	NXvseYk4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mlf6TWM2OD1zLki5PVQ3KM7:TR?=	MlHFV2FPT0WU
NB6	NVLneHN7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3;JU2lEPTB;MT65NVI6QCEQvF2=	MXLTRW5ITVJ?
EW-22	MkP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYmz[IZQUUN3ME2xMlkzQDh5IN88US=>	MkXvV2FPT0WU
ES6	NXTGXJNtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1jpVGlEPTB;MT65N\|Y{OSEQvF2=	M2f0fXNCVkeHUh?=
SCC-15	NGXObnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NETLbGRKSzVyPUGuPVM5OTlizszN	MmK5V2FPT0WU
HL-60	M1exbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHnNNYVKSzVyPUGuPVM6ODJizszN	Mn:xV2FPT0WU
human HOP-92	NHyxc49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NELvfIpKSzVyPUGuPVQxPjVizszN	NG\ZbnRUSU6JRWK=
SW626	M13DXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWLJR\|UxRTFwOUS4PVkh\|ryP	M3rxO3NCVkeHUh?=
HEC-1	NYLifWQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVi5UnZJUUN3ME2xMlk2OzZizszN	NEXWRWlUSU6JRWK=
LB2241-RCC	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlnmTWM2OD1zLkm4NlMyKM7:TR?=	M{T3OnNCVkeHUh?=
Ramos-2G6-4C10	MmS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVzJR\|UxRTFwOUm0PVMh\|ryP	NXnRO4N4W0GQR1XS
A101D	NIW1eHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIi0SWpKSzVyPUKuNlA{ODNizszN	M3vqc3NCVkeHUh?=
NCI-H446	M2\LcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn70TWM2OD1{LkC0OVk6KM7:TR?=	NYnQfoxvW0GQR1XS
SBC-5	M{Lw[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF;RXnFKSzVyPUKuNFYyPDdizszN	MmPoV2FPT0WU
HOS	MnLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NY\weXdQUUN3ME2yMlA4PjV\|IN88US=>	MnK0V2FPT0WU
K5	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWnsfJdOUUN3ME2yMlA4QDFzIN88US=>	MoXJV2FPT0WU
HLE	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3zNRmlEPTB;Mj6wPFUzQSEQvF2=	MVrTRW5ITVJ?
HSC-2	Mn;hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2ThUWlEPTB;Mj6xNlg6QCEQvF2=	NHrLWXpUSU6JRWK=
LCLC-97TM1	NF61XmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHnPd3BKSzVyPUKuNVQ2QDNizszN	M1naPHNCVkeHUh?=
DMS-273	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWXNeW5pUUN3ME2yMlE1QDN5IN88US=>	NHrhSYJUSU6JRWK=
TE-8	M4Pjfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmfQTWM2OD1{LkG1O\|Y2KM7:TR?=	MV;TRW5ITVJ?
DSH1	NWnTeFhiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYrWN4xpUUN3ME2yMlE3Ozl6IN88US=>	MoG0V2FPT0WU
CAL-51	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1uwN2lEPTB;Mj6xOlY6QSEQvF2=	MVvTRW5ITVJ?
IST-SL1	M1HPSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2PReGlEPTB;Mj6xOlg1PCEQvF2=	MVzTRW5ITVJ?
GCT	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1roWWlEPTB;Mj6xO\|c4KM7:TR?=	NYHrd5hwW0GQR1XS
SW948	NFTOcnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mo\qTWM2OD1{LkG4OFU3KM7:TR?=	Mo[wV2FPT0WU
NOMO-1	M{DGUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIHQW5RKSzVyPUKuNVk{OTdizszN	M4ezb3NCVkeHUh?=
C8166	NV3qU4NRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVjJR\|UxRTJwMkGzN\|Qh\|ryP	MoHDV2FPT0WU
OC-314	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWe0UYFTUUN3ME2yMlI{OjV7IN88US=>	NHj6fmFUSU6JRWK=
CAL-39	MkPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4jve2lEPTB;Mj6yN\|YzPiEQvF2=	M33RdXNCVkeHUh?=
MDA-MB-453	MnnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3fheGlEPTB;Mj6yOFI4PSEQvF2=	NHv3bYZUSU6JRWK=
A673	MnfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGK0dINKSzVyPUKuNlU5PjJizszN	MmrxV2FPT0WU
HTC-C3	NF6yV5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoTyTWM2OD1{LkK2PFUh\|ryP	M1WzVHNCVkeHUh?=
NCI-H1666	M4Owbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHHp[oRKSzVyPUKuNlgyOTFizszN	NYO0NnFQW0GQR1XS
PSN1	M2PMOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWPSbFVnUUN3ME2yMlI5QTF\|IN88US=>	M2HqfHNCVkeHUh?=
GI-1	M1PKXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnS4TWM2OD1{LkOwOVQ{KM7:TR?=	NXz2WmplW0GQR1XS
HuH-7	NVezUY1LT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnP4TWM2OD1{LkOwOlM4KM7:TR?=	NVrnNYw6W0GQR1XS
JAR	M4jQcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1LiPWlEPTB;Mj6zNVk5PyEQvF2=	MkHGV2FPT0WU
5637	NX7DfmR3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoXXTWM2OD1{LkOyNVI6KM7:TR?=	M1q1XHNCVkeHUh?=
GB-1	MmfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUDJR\|UxRTJwM{KzN\|Uh\|ryP	M2CxU3NCVkeHUh?=
KP-N-YS	Mnq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlHhTWM2OD1{LkOyOlE2KM7:TR?=	MULTRW5ITVJ?
OAW-42	NIHRRXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUnJR\|UxRTJwM{O0NVYh\|ryP	MVfTRW5ITVJ?
8-MG-BA	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1\Kd2lEPTB;Mj6zN\|kxPiEQvF2=	NWjVblJGW0GQR1XS
RH-18	M4SxTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUfJR\|UxRTJwM{WwNlIh\|ryP	NEDX[\|JUSU6JRWK=
NCI-H1155	MmfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1[0TGlEPTB;Mj6zOlczPSEQvF2=	M3n5PXNCVkeHUh?=
NB17	M1fr[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFHvZnhKSzVyPUKuN\|gzPDNizszN	Mlu5V2FPT0WU
NCI-H1437	M{ftN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF\zdlhKSzVyPUKuOFE5PzNizszN	MkDUV2FPT0WU
SN12C	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWLJR\|UxRTJwNEOyNVQh\|ryP	MmX6V2FPT0WU
HSC-3	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MW\JR\|UxRTJwNES1NFkh\|ryP	MVHTRW5ITVJ?
GAMG	M{TTbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYqy[HB[UUN3ME2yMlQ1PTZzIN88US=>	NFHQbmVUSU6JRWK=
HT-1080	M2LQeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVnBW4tqUUN3ME2yMlQ1QDZ2IN88US=>	NYi4PVRpW0GQR1XS
A549	M37OOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHLVcopKSzVyPUKuOFQ5QTNizszN	NWHnVFk{W0GQR1XS
KNS-62	MnvLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4jzUGlEPTB;Mj60OVA3OSEQvF2=	NVHSdohiW0GQR1XS
YKG-1	NUX5TG5XT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVLJR\|UxRTJwNEW0N\|ch\|ryP	MWrTRW5ITVJ?
LU-134-A	NGjQOGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4\DVWlEPTB;Mj60O\|AxQCEQvF2=	M{PRV3NCVkeHUh?=
FADU	NImyVpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGjaNGpKSzVyPUKuOFcyPjJizszN	NEDDfGVUSU6JRWK=
TGBC11TKB	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlzCTWM2OD1{LkS3NVc4KM7:TR?=	MX\TRW5ITVJ?
HT-3	NWPrVHh7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEC0R2dKSzVyPUKuOFk2OzVizszN	MYDTRW5ITVJ?
NCI-H2170	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NY[1UWd5UUN3ME2yMlUxPTR7IN88US=>	NFywWJJUSU6JRWK=
Mo-T	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYqyUVV1UUN3ME2yMlUxQTJ5IN88US=>	NIHSTWZUSU6JRWK=
CCRF-CEM	M4jaWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVHJR\|UxRTJwNUOwOFMh\|ryP	MV;TRW5ITVJ?
KU-19-19	M4TEcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mkf6TWM2OD1{LkWzOVE{KM7:TR?=	MXLTRW5ITVJ?
NCI-H1048	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGjhfGpKSzVyPUKuOVUxOjVizszN	NVXL[I5xW0GQR1XS
KOSC-2	MofxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnTLTWM2OD1{LkW2NFc3KM7:TR?=	NFvzU\|RUSU6JRWK=
A431	M4XaTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWTjfm0{UUN3ME2yMlU3OzN3IN88US=>	MXXTRW5ITVJ?
COR-L23	NFPGOHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHv5TGRKSzVyPUKuOVg2PjZizszN	MXXTRW5ITVJ?
MKN28	MlHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWjvfFNYUUN3ME2yMlU6ODN5IN88US=>	MXvTRW5ITVJ?
22RV1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NY[0SIp7UUN3ME2yMlU6Ojd2IN88US=>	MWXTRW5ITVJ?
ABC-1	NY\5UY5KT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoPHTWM2OD1{Lk[wOFYh\|ryP	MXnTRW5ITVJ?
NCI-H2126	NHrzSXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXzqVldpUUN3ME2yMlYxQTh2IN88US=>	MUfTRW5ITVJ?
DoTc2-4510	M17GSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUjJR\|UxRTJwNkKxPFUh\|ryP	NUHFdYlVW0GQR1XS
SCC-4	NYHJbIJHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFLrXodKSzVyPUKuOlMxOTJizszN	MlH1V2FPT0WU
NCI-H661	NWThfFdHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHvXOVNKSzVyPUKuOlQxQDVizszN	MVXTRW5ITVJ?
RPMI-2650	M{\WWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NI\0RlhKSzVyPUKuOlQyPDNizszN	Ml;PV2FPT0WU
NCI-H510A	NYrIc3Z2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2jQNmlEPTB;Mj62OFQzPiEQvF2=	NIHuNFRUSU6JRWK=
BPH-1	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnPLTWM2OD1{Lk[1PFUh\|ryP	MonGV2FPT0WU
M14	NY\tO2x[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIPIclVKSzVyPUKuOlY6QTNizszN	MVPTRW5ITVJ?
G-402	MojWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2\4TmlEPTB;Mj63NFQ2OSEQvF2=	M4\kdHNCVkeHUh?=
AsPC-1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlHBTWM2OD1{LkexNVch\|ryP	NWrwVmNRW0GQR1XS
NB12	NH;SO5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4HHT2lEPTB;Mj63NVcyKM7:TR?=	MX\TRW5ITVJ?
SK-HEP-1	NUPveXhGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoO3TWM2OD1{Lke0N\|kyKM7:TR?=	NV7x[HBtW0GQR1XS
U-266	NVjVdGR1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{TDbGlEPTB;Mj63O\|EzOSEQvF2=	NUHYfYttW0GQR1XS
AM-38	NF7UbIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV;JR\|UxRTJwN{ezOVUh\|ryP	MUPTRW5ITVJ?
PC-14	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3zofmlEPTB;Mj64NFUyKM7:TR?=	M2n5XHNCVkeHUh?=
EGI-1	NG\F[YFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYfLR5RjUUN3ME2yMlgyPzR\|IN88US=>	MmDDV2FPT0WU
LS-411N	NIG3fY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWrqbJdFUUN3ME2yMlgzOzNizszN	MUnTRW5ITVJ?
BFTC-905	NHezT3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1TmUWlEPTB;Mj64OVUzOyEQvF2=	NEfrdoJUSU6JRWK=
CaR-1	NG[0XYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGnDO\|VKSzVyPUKuPFYh\|ryP	NITUT\|FUSU6JRWK=
NCI-H292	NI\HS45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2KwfWlEPTB;Mj64OlU6PiEQvF2=	MknNV2FPT0WU
8305C	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXr0bFZpUUN3ME2yMlg3PjR3IN88US=>	NYLMeHQ6W0GQR1XS
SNU-449	MoLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFXwfVRKSzVyPUKuPFkyQDJizszN	MmTiV2FPT0WU
LCLC-103H	M4[5cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXm0TGlzUUN3ME2yMlkxPDN6IN88US=>	NELZd3JUSU6JRWK=
SW1573	NGrRcVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mmq5TWM2OD1{Lkm2NFgzKM7:TR?=	NVHZNXg{W0GQR1XS
MLMA	NYLuZY9sT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnfPTWM2OD1{Lkm2O\|E4KM7:TR?=	NIXo[XVUSU6JRWK=
NCI-H1355	M1fCfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFr4VZBKSzVyPUOuNFA4QTZizszN	NHznWZdUSU6JRWK=
RMG-I	NEnjc2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoLDTWM2OD1\|LkCyOVkzKM7:TR?=	NYLibXN7W0GQR1XS
BB65-RCC	NYDoZokxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1rTe2lEPTB;Mz6wN\|MyPCEQvF2=	NHvRT21USU6JRWK=
PC-3	NULpe41vT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVnJR\|UxRTNwMEO4O\|Qh\|ryP	MoLYV2FPT0WU
SF268	NU\PSVFpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{TVWmlEPTB;Mz6wOFUzOyEQvF2=	M{\tSnNCVkeHUh?=
NCI-H810	MmGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYnJR\|UxRTNwMES4NlMh\|ryP	NFHad4xUSU6JRWK=
MEG-01	MkLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVfQdolMUUN3ME2zMlA3OTZ2IN88US=>	MUDTRW5ITVJ?
SW13	MnS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2TBTmlEPTB;Mz6wO\|g1PyEQvF2=	M{\ncnNCVkeHUh?=
RH-1	NVP1XZRFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYfJR\|UxRTNwMUCyO\|gh\|ryP	MnjzV2FPT0WU
GT3TKB	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXPJR\|UxRTNwMUGyPFMh\|ryP	MmrYV2FPT0WU
TK10	NXu5eFl4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M17JTmlEPTB;Mz6xN\|czPCEQvF2=	NUHq[25OW0GQR1XS
T-24	NFzKOmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlmwTWM2OD1\|LkG1NFch\|ryP	M1Lkb3NCVkeHUh?=
A498	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWPLVVZXUUN3ME2zMlIxQDdzIN88US=>	M3nNVnNCVkeHUh?=
GR-ST	NGnsUJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYnEbnZ4UUN3ME2zMlIzOTN7IN88US=>	NGfrSVVUSU6JRWK=
LB2518-MEL	MmjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV3JR\|UxRTNwMkKzPVgh\|ryP	NGfrbo1USU6JRWK=
T47D	M1LuWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX\JR\|UxRTNwMkO2Nlch\|ryP	NUPOToh6W0GQR1XS
NCI-H1651	NYXtWJB{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1fze2lEPTB;Mz6yOFY1PCEQvF2=	MoTQV2FPT0WU
EC-GI-10	MoLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlSzTWM2OD1\|LkK2NVU{KM7:TR?=	MlzwV2FPT0WU
HT-29	NGPLb2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVK4e5BVUUN3ME2zMlI3PjF2IN88US=>	MUDTRW5ITVJ?
GI-ME-N	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn3NTWM2OD1\|LkK5OVEyKM7:TR?=	MnG4V2FPT0WU
SW756	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX;TO4lmUUN3ME2zMlI6PjJ7IN88US=>	NUnaTZJPW0GQR1XS
RKO	NHLkc25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYHE[oREUUN3ME2zMlMxPzV5IN88US=>	MULTRW5ITVJ?
NCI-H1563	MlXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYrJR\|UxRTNwM{OwNVgh\|ryP	MX7TRW5ITVJ?
DJM-1	Mne1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUPJR\|UxRTNwM{e2O\|Qh\|ryP	NF3kcnNUSU6JRWK=
L-428	NGe4ZlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWCxWGJQUUN3ME2zMlQxODR3IN88US=>	Moj2V2FPT0WU
NCI-H2122	Mn\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHrYOGtKSzVyPUOuOFE{OTJizszN	M2TnXHNCVkeHUh?=
Ca-Ski	MlLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmqzTWM2OD1\|LkS1OFMh\|ryP	NILmVI5USU6JRWK=
639-V	M{XCcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF;FSGpKSzVyPUOuOFYxPTdizszN	NG\VcplUSU6JRWK=
SW1116	Ml:yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYfJR\|UxRTNwNE[yOlkh\|ryP	MoHpV2FPT0WU
DMS-114	NX;zRXFiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFXHS2dKSzVyPUOuOFcxPjZizszN	Mmf0V2FPT0WU
MZ2-MEL	NXmyXlFiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2LhZWlEPTB;Mz60O\|Y5OSEQvF2=	NVfpSm1bW0GQR1XS
COLO-829	M1HKeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1jzV2lEPTB;Mz61NFA4OyEQvF2=	NIDvVIdUSU6JRWK=
J82	M4T3R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIDMPWZKSzVyPUOuOVA2PyEQvF2=	NWe0PJdoW0GQR1XS
EW-13	M3TVb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYnJR\|UxRTNwNUK1NUDPxE1?	MV;TRW5ITVJ?
RXF393	NXm3OFBDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF;KVHRKSzVyPUOuOVMzQTRizszN	MUDTRW5ITVJ?
CAL-62	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGD6cm5KSzVyPUOuOVQ2OTRizszN	M4XEfnNCVkeHUh?=
OCUB-M	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn;vTWM2OD1\|LkW0OlY2KM7:TR?=	NInUc5hUSU6JRWK=
BT-474	M{nKVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVvJR\|UxRTNwNkOzNUDPxE1?	NYj2R\|ZNW0GQR1XS
KYSE-180	NIqy[HZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUnsO4RRUUN3ME2zMlY{Ozd{IN88US=>	NFfvN\|lUSU6JRWK=
NCI-H650	NI\yWmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVnJR\|UxRTNwNkSyPFch\|ryP	MXHTRW5ITVJ?
Detroit562	M4Hmc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX;IUoFlUUN3ME2zMlY2ODJ{IN88US=>	NE\zUnFUSU6JRWK=
SW48	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlS1TWM2OD1\|Lk[1OlU4KM7:TR?=	MYLTRW5ITVJ?
KYSE-450	NIn2VGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH;a[o1KSzVyPUOuOlg2QDJizszN	NYr3R\|RyW0GQR1XS
KYSE-510	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVHJR\|UxRTNwN{KxPFEh\|ryP	M2HqbXNCVkeHUh?=
GP5d	NWTmN4tmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmLITWM2OD1\|LkeyPVUh\|ryP	MmLwV2FPT0WU
RPMI-7951	NUPLXG9JT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV\CO2p7UUN3ME2zMlc1PzJ\|IN88US=>	MY\TRW5ITVJ?
Becker	M4nydmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmeyTWM2OD1\|Lke1NFEzKM7:TR?=	MWPTRW5ITVJ?
WM-115	NYC2eZh3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmHETWM2OD1\|Lke4NVk2KM7:TR?=	Mor6V2FPT0WU
G-401	NUnWT3pZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXHJR\|UxRTNwN{mwPFUh\|ryP	MXTTRW5ITVJ?
PANC-08-13	Mly1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFi5WJVKSzVyPUOuO\|k3ODJizszN	MU\TRW5ITVJ?
SW982	M4nRcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGnFWndKSzVyPUOuPFA2PTFizszN	MkHhV2FPT0WU
D-263MG	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYXBd4x4UUN3ME2zMlgzODVzIN88US=>	MlPJV2FPT0WU
KM-H2	NFvFdHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWPJR\|UxRTNwOEK2NlQh\|ryP	MXzTRW5ITVJ?
SK-MEL-3	M3rJWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1jxeWlEPTB;Mz64Nlg1OSEQvF2=	NGHQWJJUSU6JRWK=
NCI-H1581	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4jF[WlEPTB;Mz64OFQ5QCEQvF2=	NVfJRm4{W0GQR1XS
LS-123	Mnv4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1P1VGlEPTB;Mz64O\|kxQSEQvF2=	MV\TRW5ITVJ?
CAKI-1	NUS5e41HT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1\nfGlEPTB;Mz64PVA2OiEQvF2=	M1roZnNCVkeHUh?=
MEL-JUSO	MnHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4nHVGlEPTB;Mz64PVE2OyEQvF2=	MnPPV2FPT0WU
HCE-4	Mn7ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1XY[2lEPTB;Mz65NVY3OyEQvF2=	MnTlV2FPT0WU
TE-10	NH:xVnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MorxTWM2OD1\|LkmyNFEh\|ryP	NWTqWZJDW0GQR1XS
OVCAR-4	NXTE[VhyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2rq[mlEPTB;Mz65Nlg5QSEQvF2=	MnrKV2FPT0WU
ETK-1	NInUSWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmftTWM2OD1\|Lkm0OlM2KM7:TR?=	Ml3rV2FPT0WU
A2780	NEHZW3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXHqZZROUUN3ME20MlA2QTZ4IN88US=>	M{LxRnNCVkeHUh?=
LU-65	M4L2Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlG0TWM2OD12LkC3OlM{KM7:TR?=	MWDTRW5ITVJ?
BHY	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NILnTVJKSzVyPUSuNVI1QTVizszN	MniyV2FPT0WU
COR-L105	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWjGPVNEUUN3ME20MlE{ODVzIN88US=>	NWHwUoRTW0GQR1XS
CAL-12T	M3fXb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUjJR\|UxRTRwMUOxNFMh\|ryP	MkPaV2FPT0WU
SCH	NX31Omw3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV\JR\|UxRTRwMUW3OFMh\|ryP	M4OwVXNCVkeHUh?=
CW-2	M4m5XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEnQSlRKSzVyPUSuNVkxODFizszN	NGG1XFBUSU6JRWK=
HCC1806	NWPOZo9rT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWXjO5hjUUN3ME20MlIxOzF{IN88US=>	M3vtV3NCVkeHUh?=
KP-N-YN	MorPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUHJR\|UxRTRwMkC5Nlch\|ryP	MmTvV2FPT0WU
T98G	Mn3yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoPMTWM2OD12LkKyNVU4KM7:TR?=	MnzJV2FPT0WU
CAL-54	NGm2RmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHLrN41KSzVyPUSuNlI{QDFizszN	M3LmNnNCVkeHUh?=
CAL-33	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3f0d2lEPTB;ND6yN\|A3PCEQvF2=	NIHQU2tUSU6JRWK=
SNU-C2B	M{X4emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2XOTGlEPTB;ND6yOFc3QSEQvF2=	MXvTRW5ITVJ?
NUGC-3	MlW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2ryRmlEPTB;ND6yOVUxPSEQvF2=	MVTTRW5ITVJ?
DOK	NFu1[YZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmHUTWM2OD12LkK2OVk{KM7:TR?=	NIXl[o5USU6JRWK=
MMAC-SF	NIjTWWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1LMfGlEPTB;ND6yOlg2QSEQvF2=	MVXTRW5ITVJ?
KYSE-70	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHSwNXJKSzVyPUSuNlk{PCEQvF2=	M4DFOXNCVkeHUh?=
A204	NELoWWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1rRbWlEPTB;ND6zOVgxOyEQvF2=	MWHTRW5ITVJ?
SCC-25	M4jWT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWXEdYdrUUN3ME20MlM2QDF7IN88US=>	NIO4cY5USU6JRWK=
EPLC-272H	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF:5OFdKSzVyPUSuN\|g6PSEQvF2=	MV7TRW5ITVJ?
CAL-120	NF;EWnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWnJR\|UxRTRwM{i5PVIh\|ryP	MV;TRW5ITVJ?
LS-513	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWDvO4NZUUN3ME20MlQzOTl6IN88US=>	NG[yeZFUSU6JRWK=
CAPAN-1	M3\KNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGTxcJVKSzVyPUSuOFI{QDJizszN	M2DFSHNCVkeHUh?=
ESS-1	MkDDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoS3TWM2OD12LkSyO\|I1KM7:TR?=	MkfwV2FPT0WU
GMS-10	NX25[2N{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmT4TWM2OD12LkSyPFE6KM7:TR?=	M3;wbnNCVkeHUh?=
NCI-N87	M336W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml7ZTWM2OD12LkWwPFY5KM7:TR?=	Ml6zV2FPT0WU
HMV-II	NHjTSodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkDqTWM2OD12LkWxO\|Mh\|ryP	MUTTRW5ITVJ?
COLO-741	NVjGTFV6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF\q[5dKSzVyPUSuOVU6QTRizszN	MY\TRW5ITVJ?
MKN45	NFT5R2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFixeZpKSzVyPUSuOVc4OzJizszN	MkfBV2FPT0WU
OAW-28	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVHJR\|UxRTRwNUizPVgh\|ryP	MlX0V2FPT0WU
OCI-AML2	NFrmWlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnvuTWM2OD12Lk[1NlM5KM7:TR?=	NGn0VJNUSU6JRWK=
MDA-MB-231	NID3SYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUH2fG5nUUN3ME20MlcxOjR\|IN88US=>	MVPTRW5ITVJ?
NCI-H1648	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXjJR\|UxRTRwN{KyO\|Mh\|ryP	M1LEbnNCVkeHUh?=
NCI-H1792	NWjmdZo{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1\s[GlEPTB;ND63OlExPyEQvF2=	NE\GXI9USU6JRWK=
GCIY	M{KzdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnHyTWM2OD12Lke3OFI1KM7:TR?=	M4ThRnNCVkeHUh?=
Hs-578-T	MnvsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1vsVGlEPTB;ND63O\|Y2PSEQvF2=	NFjlT4tUSU6JRWK=
SW962	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mke2TWM2OD12Lke4NFEyKM7:TR?=	MkDQV2FPT0WU
NCI-H630	NYH0b\|FCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUjJR\|UxRTRwN{iwPFEh\|ryP	NVHxd\|c2W0GQR1XS
786-0	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYnJR\|UxRTRwN{i3O\|Mh\|ryP	MVfTRW5ITVJ?
FTC-133	NULOdpU4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWLJR\|UxRTRwN{myOlMh\|ryP	MkT4V2FPT0WU
BT-20	NHn4NWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUDsO4JPUUN3ME20Mlc6PDJ7IN88US=>	NFrLR\|lUSU6JRWK=
Mewo	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mm\PTWM2OD12LkixO\|Q4KM7:TR?=	M4LuOnNCVkeHUh?=
SW780	NIm3eHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYKwflVTUUN3ME20Mlg2PzZ4IN88US=>	MoLvV2FPT0WU
OE33	M2PtOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX\0VGkyUUN3ME20Mlg4PzF\|IN88US=>	NH3vSo1USU6JRWK=
HCC1569	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH35[YZKSzVyPUSuPFg1PThizszN	NHnRbnlUSU6JRWK=
TE-6	M3jmfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoPlTWM2OD12LkmzPVc4KM7:TR?=	MluzV2FPT0WU
SK-N-FI	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYDBdJY4UUN3ME20Mlk1PDJzIN88US=>	MV;TRW5ITVJ?
PANC-03-27	M{S5U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3HXNWlEPTB;ND65PVk3OiEQvF2=	MmK2V2FPT0WU
MCF7	NHvQRWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFz6PZlKSzVyPUWuNFA4OzhizszN	MnK5V2FPT0WU
UACC-257	NVnhUFU2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1zncmlEPTB;NT6wNlg1PSEQvF2=	M4ex[nNCVkeHUh?=
SW1088	MmfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{DOemlEPTB;NT6wNlk1PCEQvF2=	MmiwV2FPT0WU
A704	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmPSTWM2OD13LkCzNFYh\|ryP	NGDTWGVUSU6JRWK=
A2058	NGfZNpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXXJR\|UxRTVwMEW5NFgh\|ryP	M3ToN3NCVkeHUh?=
Calu-3	NGjsTFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4rnT2lEPTB;NT6wOlQ2OiEQvF2=	NWPGcYp1W0GQR1XS
RERF-LC-MS	NXWwT2Y6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVfOcnI5UUN3ME21MlA3QTB\|IN88US=>	NGPQZZZUSU6JRWK=
AU565	NG\4PXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1zBc2lEPTB;NT6wPVcxOiEQvF2=	NWmyRpp[W0GQR1XS
DMS-79	MonyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUnJR\|UxRTVwMUO4PFMh\|ryP	M3yzSnNCVkeHUh?=
DK-MG	M33ERWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4Lye2lEPTB;NT6xPFQ{QCEQvF2=	MUDTRW5ITVJ?
HuCCT1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmfXTWM2OD13LkKzPFU3KM7:TR?=	Ml3kV2FPT0WU
HT-144	MlrZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVPJR\|UxRTVwMkS5PFch\|ryP	NGmxTlZUSU6JRWK=
M059J	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV\adpNsUUN3ME21MlI2PzZizszN	M2XtXnNCVkeHUh?=
COLO-792	NETFWYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYfJR\|UxRTVwMk[zOVYh\|ryP	MX7TRW5ITVJ?
SF539	NHHvNpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmHyTWM2OD13LkK2OlMzKM7:TR?=	NGf1OoNUSU6JRWK=
SK-UT-1	NHXZc\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlXoTWM2OD13LkK3O\|UyKM7:TR?=	M{PwOHNCVkeHUh?=
NCI-H1703	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWTJR\|UxRTVwM{W4NlYh\|ryP	MX3TRW5ITVJ?
SW837	NVvLS2U3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkWxTWM2OD13LkO3PFc5KM7:TR?=	M{nPPXNCVkeHUh?=
U251	MlLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIHuRYxKSzVyPUWuN\|kxQTZizszN	MoTaV2FPT0WU
SW1710	M3LrPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoDuTWM2OD13LkSxOVU1KM7:TR?=	MoXvV2FPT0WU
NCI-H1299	NHfrb5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUC2eJhZUUN3ME21MlQ3OzN3IN88US=>	NYq2NpVPW0GQR1XS
RVH-421	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVnnNItsUUN3ME21MlQ6QTB6IN88US=>	NHPqNG1USU6JRWK=
UM-UC-3	M2C1TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1Hs[2lEPTB;NT62NlY2OSEQvF2=	M1nhbHNCVkeHUh?=
MDA-MB-175-VII	NXHSXVJoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmDPTWM2OD13Lk[0NFQyKM7:TR?=	MmnuV2FPT0WU
KYSE-270	M{\4O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn;xTWM2OD13Lk[2NFMyKM7:TR?=	NGC1bmlUSU6JRWK=
COLO-668	M3voNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3;kRWlEPTB;NT63NVMzKM7:TR?=	NFLUcVBUSU6JRWK=
LN-405	MonVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV;telZMUUN3ME21Mlc{ODh3IN88US=>	MYHTRW5ITVJ?
HT-1376	M{LUd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEDwXY9KSzVyPUWuO\|gxPTJizszN	NHzWOJlUSU6JRWK=
769-P	NFjoTZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1rM[2lEPTB;NT64OlcyQCEQvF2=	MmHwV2FPT0WU
HuP-T3	M3H6eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWLJR\|UxRTVwOEi2O\|ch\|ryP	NGTQd5BUSU6JRWK=
MDA-MB-415	NELCeYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUDJR\|UxRTVwOUKxN\|kh\|ryP	NUPTXnRpW0GQR1XS
MKN7	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIP3UYNKSzVyPUWuPVg5KM7:TR?=	NEDId4VUSU6JRWK=
KS-1	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUTJR\|UxRTVwOUi4N\|Yh\|ryP	MojGV2FPT0WU
647-V	M2S2Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{PaNmlEPTB;NT65PVE1QCEQvF2=	NXzUWY9vW0GQR1XS
COLO-679	NYf3WYVDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGT6Z4JKSzVyPU[uNFAzPTVizszN	MUHTRW5ITVJ?
AN3-CA	NFH6folIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV7vOHh7UUN3ME22MlA{PDRzIN88US=>	MmfYV2FPT0WU
C32	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlzNTWM2OD14LkGzNFM1KM7:TR?=	Ml3BV2FPT0WU
KM12	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHfXOJBKSzVyPU[uNlQxQTlizszN	MXPTRW5ITVJ?
KINGS-1	NGPMcGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGLZR3RKSzVyPU[uNlYyPTJizszN	Ml\WV2FPT0WU
KYSE-410	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIrKT21KSzVyPU[uN\|A3PDVizszN	M1K0[XNCVkeHUh?=
HPAF-II	M3LITWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX7OfJhlUUN3ME22MlM2PDhizszN	M3XYO3NCVkeHUh?=
LAN-6	NYLxPHdlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUnZPI9XUUN3ME22MlQ6PjNzIN88US=>	NH;nXJJUSU6JRWK=
LU-99A	NHHkOoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnjETWM2OD14LkW1PVg6KM7:TR?=	MVjTRW5ITVJ?
SJSA-1	NXfGS\|dzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXjJR\|UxRTZwNU[zOFch\|ryP	NHHETFBUSU6JRWK=
MSTO-211H	NWXIWJI5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVmzWlBwUUN3ME22MlczOjN\|IN88US=>	M{n1fHNCVkeHUh?=
SW900	M3rFd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXXLfJh5UUN3ME22Mlc3OjJzIN88US=>	MUHTRW5ITVJ?
LNCaP-Clone-FGC	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHzYO4JKSzVyPU[uPFA1ODNizszN	M2DmfXNCVkeHUh?=
OMC-1	NWTZSGJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3r2WWlEPTB;Nj64OVQxOiEQvF2=	NITycpdUSU6JRWK=
IST-MEL1	NXS0[pNOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIH3VY9KSzVyPU[uPFk3PjlizszN	MYHTRW5ITVJ?
TE-9	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmPyTWM2OD14Lki5PFQ4KM7:TR?=	MVzTRW5ITVJ?
NCI-H2030	NU\MeJFZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmmzTWM2OD14LkmxNlI3KM7:TR?=	NXjaV5ROW0GQR1XS
BFTC-909	NUjz[HM5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{PwUGlEPTB;Nz6wNFY1OSEQvF2=	M2rBPHNCVkeHUh?=
NCI-SNU-5	NVjE[HE6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXGxNpN{UUN3ME23MlAzOTV7IN88US=>	NUXBTXJsW0GQR1XS
TE-5	M2exRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGmwS5VKSzVyPUeuNFI5QDFizszN	NEnqZ4dUSU6JRWK=
SK-MES-1	M1S5Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkDGTWM2OD15LkC1OFI4KM7:TR?=	NWT5c2VuW0GQR1XS
SHP-77	NUf2XWVKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV7xRXQ5UUN3ME23MlE{QTV{IN88US=>	M4n4SHNCVkeHUh?=
NCI-H1623	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYnJR\|UxRTdwMUSwO\|Ih\|ryP	MmPlV2FPT0WU
TE-11	MnP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIPlb21KSzVyPUeuNVUyQDRizszN	MUnTRW5ITVJ?
EKVX	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXzJR\|UxRTdwMUmyOlch\|ryP	MUnTRW5ITVJ?
OVCAR-3	NI\WcZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkiyTWM2OD15LkKxNVM{KM7:TR?=	NFj4OIxUSU6JRWK=
C3A	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGjR[4RKSzVyPUeuN\|Q2OiEQvF2=	NWr5eWFHW0GQR1XS
CFPAC-1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUnpUoFHUUN3ME23MlM3OjJ{IN88US=>	MYXTRW5ITVJ?
MG-63	M4\EcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHT2WlJKSzVyPUeuOFE5PDlizszN	M1npS3NCVkeHUh?=
KYSE-140	NF7TUWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUTBTY1uUUN3ME23MlQ1ODZzIN88US=>	MnnIV2FPT0WU
MPP-89	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFnnVWZKSzVyPUeuOVk4OjlizszN	NWO3VoNjW0GQR1XS
COLO-824	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUjJR\|UxRTdwN{K4OlMh\|ryP	MV7TRW5ITVJ?
SiHa	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{jsUGlEPTB;Nz64N\|cxPyEQvF2=	NHfLcYFUSU6JRWK=
SNU-387	M3LFR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlPQTWM2OD15Lki1N\|Q4KM7:TR?=	MmfqV2FPT0WU
A172	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYPJR\|UxRTdwOE[xO\|Ih\|ryP	MULTRW5ITVJ?
COLO-680N	NGHERlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2XycWlEPTB;Nz65NVc{KM7:TR?=	NYrBOFFQW0GQR1XS
HCC1395	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3\EOmlEPTB;OD6wOVQ2OiEQvF2=	M4\JXnNCVkeHUh?=
NCI-H28	NIXEW21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEDSZnFKSzVyPUiuNFU6PjNizszN	MVzTRW5ITVJ?
LC-2-ad	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1Xy[WlEPTB;OD6yNVk{PyEQvF2=	MoP2V2FPT0WU
S-117	Mn35S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWSyNop7UUN3ME24MlI2OzV\|IN88US=>	NVS2V4k5W0GQR1XS
NCI-H1838	NW\a[2lvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MY\JR\|UxRThwMkW3PFEh\|ryP	NF3YZldUSU6JRWK=
PANC-10-05	M1vzRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIPQ[HdKSzVyPUiuN\|cxPDdizszN	MmfjV2FPT0WU
KALS-1	M2rGWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVqwPZhLUUN3ME24MlUxQTJ6IN88US=>	MmK2V2FPT0WU
LS-1034	M4rZRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUXJR\|UxRThwNUe0N\|ch\|ryP	MV\TRW5ITVJ?
TGBC1TKB	M1XpWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWrJR\|UxRThwN{O1N\|Uh\|ryP	NXqxd2tnW0GQR1XS
OE19	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlLLTWM2OD16Lke2NlYzKM7:TR?=	MmXZV2FPT0WU
D-502MG	NInwUW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH:wbFZKSzVyPUiuO\|Y6QTRizszN	NFPWWFhUSU6JRWK=
JEG-3	MlGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVPJR\|UxRThwN{i2NVgh\|ryP	NVnGSlJuW0GQR1XS
DBTRG-05MG	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYDrdI9ZUUN3ME24Mlg4PTZ3IN88US=>	M37mOnNCVkeHUh?=
ME-180	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mo\PTWM2OD17LkC2O\|I2KM7:TR?=	MWLTRW5ITVJ?
NCI-H1573	MoroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2LaR2lEPTB;OT6xNFU{OiEQvF2=	MUfTRW5ITVJ?
HCC2998	MnfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4\YUWlEPTB;OT6xN\|Y5OSEQvF2=	Mmn1V2FPT0WU
ACHN	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2W5NWlEPTB;OT6yOFk4PSEQvF2=	MXHTRW5ITVJ?
D-392MG	NXT2e5MyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnfPTWM2OD17LkK1O\|E2KM7:TR?=	NUG2XFFOW0GQR1XS
no-11	NF;YUG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWTJR\|UxRTlwMk[wNlgh\|ryP	MVHTRW5ITVJ?
KLE	NG\F[HJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEPBTGtKSzVyPUmuN\|IzOzJizszN	M1y1c3NCVkeHUh?=
Calu-6	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWHDXXo2UUN3ME25MlM4PTJ6IN88US=>	NV\tNpR5W0GQR1XS
LB831-BLC	NYPlfYlCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX\SeGJLUUN3ME25MlQ2OTdzIN88US=>	M2HHeXNCVkeHUh?=
SW684	NUi3U3NjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFHSd3hKSzVyPUmuOFYyOTZizszN	M2fJfnNCVkeHUh?=
SH-4	Ml7mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUDJR\|UxRTlwNEmzOlQh\|ryP	M2\pdnNCVkeHUh?=
IST-MES1	NXH3PXRZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGLDeodKSzVyPUmuOVE3PDRizszN	MoDuV2FPT0WU
Saos-2	M{Owd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NULvboF6UUN3ME25MlUzOTl3IN88US=>	M2O4O3NCVkeHUh?=
NCI-H2087	Mn;QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3jGd2lEPTB;OT62O\|M2OiEQvF2=	NFrRUFdUSU6JRWK=
SCC-9	M2LGS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYnxTVJvUUN3ME25MlcyQDF4IN88US=>	NIe0eGRUSU6JRWK=
MFE-280	MkfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MULJR\|UxRTlwN{K3PFUh\|ryP	NH;FVJZUSU6JRWK=
BEN	Mk\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUPHVJQ3UUN3ME25MlgzOTV7IN88US=>	MXXTRW5ITVJ?
CP50-MEL-B	NYfNT4xVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWDJNpc2UUN3ME25MlkzPDN{IN88US=>	NGHU[nBUSU6JRWK=
SK-MEL-28	NHP0OFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXTJR\|UxRTFyLkCxPVMh\|ryP	NF3yfoVUSU6JRWK=
NCI-H2452	NFW3SIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH[1S4NKSzVyPUGwMlE3KM7:TR?=	MojUV2FPT0WU
NCI-H1395	M{HHZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkjUTWM2OD1zMD6xO\|gh\|ryP	MX7TRW5ITVJ?
NCI-H2052	NVzBZnpTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF[3dIpKSzVyPUGwMlE5QDJizszN	M2LZTHNCVkeHUh?=
A375	M{jRcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXfJR\|UxRTFyLkK0OVIh\|ryP	M3nE[HNCVkeHUh?=
HCC38	NEm2doZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFXCT3dKSzVyPUGwMlMzOiEQvF2=	MYHTRW5ITVJ?
LK-2	MnT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mk\RTWM2OD1zMD60NlA5KM7:TR?=	MkPGV2FPT0WU
SF126	NVTZR4JET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M324VGlEPTB;MUCuOFczPyEQvF2=	MofKV2FPT0WU
SK-MEL-1	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXTJR\|UxRTFyLke4N\|gh\|ryP	M3\xR3NCVkeHUh?=
ACN	NXL5OGt3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2HoT2lEPTB;MUCuPFY4QSEQvF2=	MYrTRW5ITVJ?
BB30-HNC	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFPBR5ZKSzVyPUGwMlg4OTFizszN	Mkj0V2FPT0WU
NCI-H747	M1rWZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M37n[2lEPTB;MUCuPFc1PiEQvF2=	MXXTRW5ITVJ?
KYSE-150	MlnuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1rrS2lEPTB;MUGuNFM5PyEQvF2=	NYTJboF2W0GQR1XS
D-247MG	NV\1bItNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mlz0TWM2OD1zMT6xNFA6KM7:TR?=	MU\TRW5ITVJ?
BxPC-3	NHXSe\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIXDWIhKSzVyPUGxMlM4PDdizszN	M3nwWnNCVkeHUh?=
SK-MEL-30	MkfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYXJR\|UxRTFzLkSwO\|kh\|ryP	M3rk[XNCVkeHUh?=
CAS-1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX\ydnEyUUN3ME2xNU41OTB7IN88US=>	NXPxW2t2W0GQR1XS
no-10	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MofaTWM2OD1zMj6xNlE4KM7:TR?=	MUHTRW5ITVJ?
NCI-H2405	NEjtV41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV60dY9KUUN3ME2xNk4zODN4IN88US=>	M3HjOXNCVkeHUh?=
KGN	NF7BRYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{f0N2lEPTB;MUKuNlkxOSEQvF2=	NW\sNI5QW0GQR1XS
BB49-HNC	M2DP[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mnf0TWM2OD1zMj6zPVU3KM7:TR?=	M4LKcXNCVkeHUh?=
NCI-H1693	NFTWfWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFX4WlBKSzVyPUGyMlU5OTZizszN	NFK0Z4NUSU6JRWK=
RO82-W-1	NWDsOI9jT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIDpXW9KSzVyPUGzMlA3PDlizszN	MYjTRW5ITVJ?
CAL-85-1	M2m5Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXvJR\|UxRTF\|LkSzPVkh\|ryP	MWXTRW5ITVJ?
H-EMC-SS	NGfZc5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVrJR\|UxRTF\|LkmxNFQh\|ryP	NUXKU4M{W0GQR1XS
SW1783	NXHEfnppT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXfJR\|UxRTF2LkKzPVEh\|ryP	Mki3V2FPT0WU
LB771-HNC	NXnKT4s3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXLPXHRFUUN3ME2xOE41OTlizszN	Ml7PV2FPT0WU
HCC70	NVfLc4p1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXvkR2kxUUN3ME2xOE41OjN\|IN88US=>	NWLqepU4W0GQR1XS
KNS-81-FD	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoW4TWM2OD1zND63NFQ2KM7:TR?=	NX;wZ3lqW0GQR1XS
KYSE-520	NEfj[nNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWrtNlhnUUN3ME2xOE46OjdizszN	MVHTRW5ITVJ?
TGBC24TKB	NHn2bphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVLJR\|UxRTF2Lkm1N\|kh\|ryP	NX7OcpI4W0GQR1XS
SNB75	NIfyO2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHfUfohKSzVyPUG1MlA4OjlizszN	NHvtSmdUSU6JRWK=
SW872	NGK2RXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlHMTWM2OD1zNT6yNlE5KM7:TR?=	NXrURYpGW0GQR1XS
U031	Ml7FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWTJR\|UxRTF3LkiwNlgh\|ryP	MkfnV2FPT0WU
ChaGo-K-1	NUfHeIVLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmHKTWM2OD1zNT64N\|U6KM7:TR?=	M1Xz[3NCVkeHUh?=
NCI-H441	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NETscpZKSzVyPUG2MlAxOzlizszN	NX36cHlCW0GQR1XS
TE-12	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mlu1TWM2OD1zNj6xPFc{KM7:TR?=	MoTCV2FPT0WU
NCI-H1755	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmDETWM2OD1zNj61O\|Mh\|ryP	MWTTRW5ITVJ?
KNS-42	Ml61S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUnmZ3NnUUN3ME2xOk43PTh7IN88US=>	MWPTRW5ITVJ?
SK-PN-DW	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXO5O2RJUUN3ME2xO{41OjBzIN88US=>	MVHTRW5ITVJ?
NCI-H226	NX7vNJpYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{HScWlEPTB;MUeuPVM1PSEQvF2=	NF7Zd2RUSU6JRWK=
K-562	NIHBXYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2HuPWlEPTB;MUiuOlMyPyEQvF2=	NEfWXpFUSU6JRWK=
A388	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVXJR\|UxRTF7LkCzNFMh\|ryP	NVLiXHZCW0GQR1XS
ZR-75-30	MmfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIfVUWVKSzVyPUG5MlA6PjhizszN	Mlf0V2FPT0WU
LU-135	MnezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHr1c\|ZKSzVyPUG5MlI3OzZizszN	M4TacnNCVkeHUh?=
NCI-H2029	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlX2TWM2OD1zOT62NFIyKM7:TR?=	NF\xdW5USU6JRWK=
HT-1197	NFPRcoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3HLRWlEPTB;MUmuPVIzPyEQvF2=	NXm0SmhyW0GQR1XS
IGR-1	M1vId2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2\RNGlEPTB;MkCuN\|EyPyEQvF2=	NFnqZ5BUSU6JRWK=
U-87-MG	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVHlRYFUUUN3ME2yNE43PDF\|IN88US=>	NFjWelZUSU6JRWK=
NCI-H1304	NEXuSHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF3LU2RKSzVyPUKwMlc2ODFizszN	M{fENHNCVkeHUh?=
RCC10RGB	M4O5PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEnTZlJKSzVyPUKxMlI5OjlizszN	MnvGV2FPT0WU
NCI-H520	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2LQc2lEPTB;MkKuO\|YyOSEQvF2=	M1LQWHNCVkeHUh?=
SK-LU-1	MnnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NI\QPYtKSzVyPUKzMlA4OThizszN	MYPTRW5ITVJ?
UACC-893	NXH2eW8yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYnJR\|UxRTJ\|LkGwN\|gh\|ryP	MYfTRW5ITVJ?
NCI-H2347	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIn4NoVKSzVyPUKzMlI3PzRizszN	MX7TRW5ITVJ?
U-118-MG	NYnuNYxYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn\ITWM2OD1{Mz63NlE4KM7:TR?=	NUL6WJpTW0GQR1XS
NCI-H596	NI\sZ4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHHzcJlKSzVyPUKzMlkxPTVizszN	MX;TRW5ITVJ?
MZ1-PC	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEDFc\|lKSzVyPUK0MlY4PTlizszN	NULldJZ5W0GQR1XS
SW1417	M3P1SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{fKWmlEPTB;MkWuNlQ6QCEQvF2=	NHfFRWVUSU6JRWK=
NCI-H82	MmK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWPJR\|UxRTJ4LkSyPFgh\|ryP	Ml3kV2FPT0WU
COLO-678	NEfKU3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkXyTWM2OD1{Nz60PVE6KM7:TR?=	NEDDcFdUSU6JRWK=
KURAMOCHI	NInKbWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWntRlIyUUN3ME2yPE4yOjZizszN	NHW3eIpUSU6JRWK=
NCI-H1650	MkHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkXKTWM2OD1\|MD6xPVI1KM7:TR?=	M3LUUHNCVkeHUh?=
HCC1954	NITIRmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXHYcYozUUN3ME2zNU4{PjZ4IN88US=>	M1;WU3NCVkeHUh?=
GAK	NEDkOFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXTSU3NQUUN3ME2zNk4zPjF4IN88US=>	NXXZ[nU6W0GQR1XS
YAPC	M3\acWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4fpW2lEPTB;M{OuO\|Y1QCEQvF2=	M2jCZnNCVkeHUh?=
NCI-H2228	M2LTW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWXJR\|UxRTN2LkO2NFUh\|ryP	NFG3em5USU6JRWK=
VMRC-RCZ	Mo\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYjJR\|UxRTN4LkOwNlIh\|ryP	NHm2b4JUSU6JRWK=
NMC-G1	M4ryeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGrnNmhKSzVyPUO3MlA2OjlizszN	Mm\kV2FPT0WU
D-336MG	NF[xTohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF3tTYVKSzVyPUSxMlg1PDJizszN	NIfPeJZUSU6JRWK=
UACC-62	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUXJR\|UxRTR{LkW1NFUh\|ryP	NHnQb4dUSU6JRWK=
C-33-A	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYTJR\|UxRTR3LkOyOVYh\|ryP	M3q2PHNCVkeHUh?=
HCC1937	NHH4d2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWTJR\|UxRTR5LkG5OVgh\|ryP	NUXTNYN[W0GQR1XS
HDLM-2	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUPJR\|UxRTR5LkKyPFch\|ryP	MkHuV2FPT0WU
NCI-H727	NVyw[YF2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUXnZnlSUUN3ME20O{4zPDVzIN88US=>	M1fTZnNCVkeHUh?=
NY	NH65TGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFn4b4ZKSzVyPUS5MlM6ODhizszN	MnvoV2FPT0WU
NCI-H2291	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2DB[mlEPTB;NEmuPFMxOSEQvF2=	MWXTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Ac-Histone H4 / Ac-Histone H3; PubMed: 21598070 J Neurooncol D54 and U87 glioma cells were treated with lower concentrations (1-3 µM) of vorinostat. The effects on histone acetylation was assessed by immunoblotting. phospho-CDK1; PubMed: 21598070 Changes in level of inhibitory phosphorylation of cdk1 after treatment with vorinostat was determined at 24 and 48 h (using a Tyr-15 residue phospho-specific antibody) along with total cdk1 as loading control. phospho-Cdc25c / Cdc25c; PubMed: 21598070 J Neurooncol Time course of changes in phospho-cdc25c levels after exposure to vorinostat (5 µM). Cyclin B1; PubMed: 21598070 J Neurooncol Cyclin B1 levels were determined in D54 and U87 cells after treatment with various doses of vorinostat at 24 and 48 h. c-Myc / c-Raf / Akt / Cyclin D1 / CDK4; PubMed: 19440035 Cancer Biol Ther Cell lysates from JeKo-1 and Mo2058 cells exposed to vorinostat were immunoblotted for c-Myc, c-Raf, AKT, cyclin D1, CDK4 and acetylated histone H3. The levels of β-actin served as the loading control. p-eIF2α / ATF4 / CHOP ; PubMed: 20072656 Neoplasia Western blot was performed to evaluate activated eIF2α (P-eIF2α), translational up-regulation of ATF4, and CHOP expression in U251 cells after vorinostat exposure. p21; PubMed: 21598070 J Neurooncol To determine the dose response relationship to vorinostat, cells were exposed to various higher concentrations (5–10 µM) of the agent and the levels of p21 determined by immunoblotting.	21598070 19440035 20072656
Immunofluorescence	HDAC1 / CK19; PubMed: 29917299 Cancer Sci Immunocytochemistry to detect the expression of HDAC1 and CK 19 in PDAC cells with/without Vorinostat treatment. HDAC1 and CK19 were stained red and green, respectively. The Hoechst‐stained nuclei appear blue. Scale bar: 100 μm. The CK19 expression in PSN1 and MiaPaCa2 was increased by Vorinostat treatment. Nrf2; PubMed: 20566897 Blood Vorinostat induced translocation of Nrf2 from cytosol to nucleus. U937 cells were treated with 2μM vorinostat for 18 hours and then cytospun. Cells were fixed and labeled for Nrf2 protein (red) and nucleus (blue, 4,6-diamidino-2-phenylindole) as described in “Immunofluorescence and confocal microscopy.” Images were taken by Nikon Eclipse TE2000 confocal microscope with 40×/1.30 numeric aperture oil objective lens. Ctrl indicates control cells without treatment; and Vor, vorinostat. α-SMA; PubMed: 26330748 Mol Vis Representative immunofluorescence images and the quantification graph showing the effect of vorinostat (2.5 µM), TGIF1, and TGIF2 siRNA knockdown on αSMA. Control human corneal fibroblast cultures (-TGFβ) showed no αSMA staining. Cultures treated with TGFβ1 (5 ng/ml) showed a robust αSMA staining. Vorinostat treatment markedly attenuated TGFβ-evoked αSMA staining. The knockdown of TGIF1 (+TGFβ+vorinostat+TGIF1siRNA) and TGIF2 alone (+TGFβ+vorinostat+TGIF2siRNA) or in combination (+TGFβ +vorinostat +TGIF1 +2siRNA) markedly blocked the effect of vorinostat on αSMA. Scale bar=100 μm. Ac-STAT3 / IGF2; PubMed: 27086926 Oncogene Immunofluorescence staining of Ac-STAT3 and IGF2 after vorinostat treatment.	29917299 20566897 26330748 27086926
Growth inhibition assay	Cell apoptosis; PubMed: 19440035 Cancer Biol Ther Cells were treated with indicated concentrations of vorinostat for 48 hours. Following this, the percentage of annexin-V-stained apoptotic cells was determined by flow cytometry. Values represented as bar graphs are the mean of 3 experiments plus or minus the standard error (SE) Cell viability; PubMed: 27086926 Oncogene The effects of vorinostat on the viability of the indicated NSCLC cell lines and their corresponding acquired VoR sublines. Cell viability was determined by the MTT assay (n = 3).	19440035 27086926
ELISA	IGF2; PubMed: 27086926 Oncogene Determination of vorinostat-induced IGF2 production by ELISA (n = 3). The conditioned mediums (CMs) obtained from cells treated with vorinostat (5 μM) for 2 days were used for ELISA. IL-13 / IL-10 / IL-5; PubMed: 18541724 Blood Effect of vorinostat on TH1/TH2 cytokine secretion in HL cell lines. Cells were incubated with medium or vorinostat (5 μM) for 24 hours and supernatants were examined for cytokine levels by ELISA. Each value represents a mean of 3 independent experiments done in triplicate (± SEM). M-CSF; PubMed: 23042302 Carcinogenesis Primary PyMT tumor cells were treated with SAHA (0-1000nM) for varying time points (8–48h), and supernatants were assayed by ELISA for M-CSF secretion. P < 0.05 and P < 0.001 versus control treatment. MMP-9; PubMed: 23042302 Carcinogenesis Primary PyMT tumor cells were treated with SAHA (0-1000nM) for varying time points (8–48h), and supernatants were assayed by ELISA for MMP-9 secretion. P < 0.05 and **P < 0.001 versus control treatment.	27086926 18541724 23042302

In vivo

Administration of Vorinostat (~100 mg/kg/day) significantly inhibits the growth of CWR22 human prostate xenografts in nude mice with tumor reductions of 78%, 97% and 97%, at doses of 25 mg/kg/day, 50 mg/kg/day and 100 mg/kg/day, respectively, compared with control. Vorinostat induces the accumulation of acetylated core histones and prostate-specific antigen mRNA expression in CWR22 cells, resulting in higher levels of serum prostate-specific antigen than predicted from tumor volume alone. ^[2] Oral administration of Vorinostat (0.67g/L) crosses the blood-brain barrier, increases histone acetylation in the brain, and dramatically improves the motor impairment in the R6/2 mice model of Huntington's disease. ^[5]

Protocol

Kinase Assay: ^[1]	- Collapse Immunoprecipitation-HDAC assays: The lysate of Jurkat cells is incubated for 1 hour on ice and cleared by centrifugation at 12,000 g for 10 minutes at 4 °C. Supernatants are precleared with 30 μL of 50% protein G-Sepharose slurry for 1 hour at 4 °C. Beads are pelleted by centrifugation and supernatants are incubated for 1 hour at 4 °C with 10 μg of IgG fraction from anti-HDAC1 or HDAC3 polyclonal antisera (preincubated 2 hours at room temperature with either the homologous or heterologous immunizing peptide). Both antisera are raised in rabbits against the carboxylterminal peptide of HDAC1 and HDAC3 by using synthetic peptides coupled to keyhole limpet hemocyanin. 30 μL of 50% protein G-Sepharose slurry is added for 1 hour at 4 °C. Immune complexes are pelleted by centrifugation and washed three times with 1 mL of lysis buffer. Beads are resuspended in 200 μL of HDAC buffer (20 mM Tris-HCl, pH 8.0/150 mM NaCl/10% glycerol), and the HDAC assay is performed with an ³H-acetylated peptide corresponding to amino acids 1-24 of histone H4. Released [³H]acetic acid is quantified by scintillation counting. For inhibitions studies, the immunoprecipitated complexes are preincubated with the different concentrations of Vorinostat for 30 minutes at 4 °C.
Cell Research: ^[2]	- Collapse Cell lines: LNCaP, PC-3, and TSU-Pr1 Concentrations: Dissolved in DMSO, final concentrations ~7.5 μM Incubation Time: 1, 2, 3 and 4 days Method: Cells are exposed to various concentrations of Vorinostat for 1, 2, 3 and 4 days. Cell viability is assessed by trypan blue dye exclusion. (Only for Reference)
Animal Research: ^[2]	- Collapse Animal Models: Male BALB/c nude (nu/nu) mice implanted with CWR22 tumor cells Formulation: Dissolved in DMSO Dosages: ~100 mg/kg/day Administration: Injection i.p. (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	52 mg/mL (196.74 mM)
	Ethanol	3 mg/mL (11.35 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Vorinostat (SAHA, MK0683) SDF

Molecular Weight	264.3
Formula	C₁₄H₂₀N₂O₃
CAS No.	149647-78-9
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	SAHA, MK0683, suberoylanilide hydroxamic acid

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03022565	Suspended	Drug: Vorinostat	Uveal Melanoma	University of Miami\|University of Miami Sylvester Comprehensive Cancer Center	January 2020	Early Phase 1
NCT03167437	Recruiting	Drug: Vorinostat	Crohn''s Disease	National Institute of Allergy and Infectious Diseases (NIAID)\|National Institutes of Health Clinical Center (CC)	October 30 2017	Phase 1\|Phase 2
NCT03056495	Recruiting	Drug: N-hydroxy-N''-phenyl-octanediamide (Vorinostat)	Alzheimer Disease	German Center for Neurodegenerative Diseases (DZNE)\|University Hospital Bonn\|University of Göttingen	September 28 2017	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
What’s the recommendation about reconstitution of the compound for in vivo animal study?
Answer:
We recommend the following vehicle for S1047: 2% DMSO, 40% PEG 300, 5% Propylene glycol, 1% Tween 80 at 5 mg/mL.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Selective HDAC Inhibitor

RGFP966 : HDAC3-selective, IC50=80 nM.
Selective HDAC Inhibitor

Rocilinostat (ACY-1215) : HDAC5-selective, IC50=5 nM.
Most Potent HDAC Inhibitor

Quisinostat (JNJ-26481585) : HDAC1, IC50=0.11 nM; HDAC2, IC50=0.33 nM.
FDA-approved HDAC Inhibitor

Vorinostat (SAHA, MK0683) : Approved by FDA against cutaneous T cell lymphoma.
Newest HDAC Inhibitor

RG2833 (RGFP109) ^New : Brain-penetrant HDAC inhibitor with IC50 of 60 nM and 50 nM for HDAC1 and HDAC3, respectively.

Related HDAC Products

LMK-235 ^New

LMK-235 is a selective inhibitor of HDAC4 and HDAC5 with IC50 of 11.9 nM and 4.2 nM, respectively.
CAY10603 ^New

CAY10603 is a potent and selective HDAC6 inhibitor with IC50 of 2 pM, >200-fold selectivity over other HDACs.
Domatinostat (4SC-202,Domatinostat) ^New

4SC-202 is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. Also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). Phase 1.
Panobinostat (LBH589)

Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.
Entinostat (MS-275)

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.
Trichostatin A (TSA)

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
Romidepsin (FK228, Depsipeptide)

Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.

Features:More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
RGFP966

RGFP966 is an HDAC3 inhibitor with IC50 of 0.08 μM in cell-free assay, exhibits > 200-fold selectivity over other HDAC.
Tubastatin A

Tubastatin A is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay. It is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold).
Mocetinostat (MGCD0103)

Mocetinostat (MGCD0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Vorinostat (SAHA, MK0683)

Cited by 259 Publications

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Vorinostat (SAHA, MK0683) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Choose Your Country or Region

By Signaling Pathways

By product type

Vorinostat (SAHA, MK0683)

Cited by 259 Publications

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Vorinostat (SAHA, MK0683) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)